As filed with the Securities and Exchange Commission
on February 3, 2023
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Kiora Pharmaceuticals, Inc.
(Exact name of registrant as specified in its
Charter)
| |
|
|
|
|
| Delaware |
|
2834 |
|
98-0443284 |
|
(State or other jurisdiction of
incorporation or organization) |
|
(Primary Standard Industrial
Classification Code Number) |
|
(I.R.S. Employer
Identification No.) |
332 Encinitas Boulevard, Suite 102, Encinitas,
California 92024
(781) 788-9043
(Address, including zip code,
and telephone number, including area code, of registrant’s principal executive office)
Brian
M. Strem, Ph.D.
President and Chief Executive Officer
Kiora Pharmaceuticals, Inc.
332 Encinitas Boulevard, Suite 102, Encinitas, California 92024
(781) 788-9043
(Name, address, including zip code, and telephone
number, including area code, of agent for service)
With copies to:
Robert A. Petitt, Esq.
Burns & Levinson LLP
125 High Street
Boston, MA 02110
(617) 345-3000 |
Approximate
date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.
If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415
under the Securities Act of 1933, check the following box. x
If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act,
check the following box and list the Securities Act registration statement number of the earlier effective registration statement for
the same offering. ¨
If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box
and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box
and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of
“large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth
company” in Rule 12b-2 of the Exchange Act. (check one)
| |
|
|
|
|
|
|
| Large Accelerated filer |
|
¨ |
|
Accelerated filer |
|
¨ |
| |
|
|
|
| Non-accelerated filer |
|
x |
|
Smaller reporting company |
|
x |
| |
|
|
|
|
|
|
| |
|
|
|
Emerging growth company |
|
¨ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act . ¨
The Registrant hereby amends this Registration Statement on such
date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states
that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of
1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting
pursuant to Section 8(a), may determine.
SUBJECT TO COMPLETION, DATED FEBRUARY
3, 2023
The information in this preliminary
prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities
and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities
in any jurisdiction where the offer or sale is not permitted.
PROSPECTUS
Up to 1,052,798 Shares of Common Stock
This prospectus relates to the offer and sale
of up to 1,052,798 shares of our Common Stock, par value $0.01 per share, by Lincoln Park Capital Fund, LLC, which we refer to in this
prospectus as Lincoln Park or the selling stockholder.
The shares of Common Stock to which this prospectus
relates consist of:
| ● | 52,798 shares of Common Stock that we have issued and sold to Lincoln Park pursuant to a securities purchase
agreement, dated as of February 2, 2023, that we entered into with Lincoln Park, which we refer to in this prospectus as the Securities
Purchase Agreement, pursuant to which we issued and sold to Lincoln Park 52,798 shares of Common Stock and warrants to purchase up to
an aggregate of 105,596 shares of Common Stock, at a purchase price per unit consisting of one share of Common Stock and two warrants
of $3.788, and for a total purchase price of $200,000, in a private placement transaction that closed on February 3, 2023, which
we refer to in this prospectus as the Private Placement; and |
| ● | Up to 1,000,000 shares of Common Stock that we may elect to issue and sell to Lincoln Park, in our sole
discretion from time to time after the date of this prospectus, pursuant to a purchase agreement, dated as of February 3, 2023, that
we entered into with Lincoln Park, which we refer to in this prospectus as the Purchase Agreement, providing for up to $10,000,000 of
committed equity financing, which we refer to in this prospectus as the Committed Equity Financing. |
We are not selling any securities under this prospectus
and will not receive any of the proceeds from the sale of our Common Stock by the selling stockholder. However, (i) we have received
$200,000 aggregate gross proceeds under the Securities Purchase Agreement from our sale to Lincoln Park of 52,798 shares of Common Stock
and warrants to purchase up to an aggregate of 105,596 shares of Common Stock on February 3, 2023 in the Private Placement and (ii) we
may receive additional aggregate gross proceeds of up to $10.0 million under the Purchase Agreement from sales of common stock we may
elect to make to Lincoln Park in our sole discretion from time to time after the date of this prospectus pursuant to the Purchase Agreement.
See the section titled “The Lincoln Park Transactions—The Private Placement” in this prospectus for a description of
the terms of the Securities Purchase Agreement and the Private Placement, the section titled “The Lincoln Park Transactions—The
Committed Equity Financing” in this prospectus for a description of the terms of the Purchase Agreement and the Committed Equity
Financing, and the section titled “Selling Stockholder” in this prospectus for additional information regarding Lincoln Park.
The selling stockholder may sell or otherwise
dispose of the Common Stock described in this prospectus in a number of different ways and at varying prices. See the section titled “Plan
of Distribution” in this prospectus for more information about how Lincoln Park may sell or otherwise dispose of the Common Stock
being registered for resale by Lincoln Park pursuant to this prospectus. Lincoln Park is an “underwriter”
within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended, or the Securities Act, with respect to the offer
and resale by Lincoln Park of up to 1,000,000 shares of Common Stock that we may issue and
sell to Lincoln Park at our sole discretion from time to time after the date of this prospectus in connection with the Committed Equity
Financing pursuant to the Purchase Agreement, and Lincoln Park may be deemed an “underwriter” within the meaning of Section 2(a)(11)
of the Securities Act with respect to the offer and resale by Lincoln Park of up to 52,798 shares of Common Stock that we have issued
and sold to Lincoln Park in the Private Placement pursuant to the Securities Purchase Agreement. We will pay the expenses incurred
in registering under the Securities Act the offer and resale of the Common Stock to which this prospectus relates by Lincoln Park, including
legal and accounting fees.
Our Common Stock is listed on The Nasdaq Capital
Market under the symbol “KPRX.” On February 2, 2023, the closing price for our Common Stock, as reported on The Nasdaq
Capital Market, was $3.56 per share.
You should read this prospectus, together with
additional information described under the headings “Incorporation of Certain Information by Reference” and “Where You
Can Find More Information,” carefully before you invest in our common stock.
Investing
in our securities involves a high degree of risk. See “Risk Factors” beginning on page 11 of this prospectus,
and under similar headings in the other documents that are incorporated by reference into this prospectus, for a discussion of information
that should be considered in connection with an investment in our securities.
Neither the U.S. Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.
The date of this prospectus is ,
2023
TABLE OF CONTENTS
ABOUT THIS PROSPECTUS
This prospectus is part of a registration statement
that we have filed with the Securities and Exchange Commission (the “SEC”) pursuant to which the selling stockholder named
herein may, from time to time, offer and sell or otherwise dispose of the securities covered by this prospectus. You should not assume
that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front cover of this
prospectus or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated
by reference, even though this prospectus is delivered or securities are sold or otherwise disposed of on a later date. It is important
for you to read and consider all information contained in this prospectus, including the information incorporated by reference herein,
in making your investment decision. You should also read and consider the information in the documents to which we have referred you under
the captions “Where You Can Find More Information” and “Incorporation of Information by Reference” in this prospectus.
Neither we nor the selling stockholder have authorized
any dealer, salesman or other person to give any information or to make any representation other than those contained or incorporated
by reference in this prospectus. You must not rely upon any information or representation not contained or incorporated by reference in
this prospectus. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any of our securities other
than the securities covered hereby, nor does this prospectus constitute an offer to sell or the solicitation of an offer to buy any securities
in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. Persons who come into
possession of this prospectus in jurisdictions outside the United States are required to inform themselves about, and to observe, any
restrictions as to the offering and the distribution of this prospectus applicable to those jurisdictions.
Unless otherwise indicated, information contained
in this prospectus concerning our industry and the markets in which we operate, including our general expectations and market position,
market opportunity and market share, is based on information from our own management estimates and research, as well as from industry
and general publications and research, surveys and studies conducted by third parties. Management estimates are derived from publicly
available information, our knowledge of our industry and assumptions based on such information and knowledge, which we believe to be reasonable.
Our management estimates have not been verified by any independent source, and we have not independently verified any third-party information.
In addition, assumptions and estimates of our and our industry’s future performance are necessarily subject to a high degree of
uncertainty and risk due to a variety of factors, including those described in “Risk Factors.” These and other factors could
cause our future performance to differ materially from our assumptions and estimates. See “Special Note Regarding Forward-Looking
Statements.”
We further note that the representations, warranties
and covenants made by us in any agreement that is filed as an exhibit to the registration statement of which this prospectus is a part
were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among
the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations,
warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should
not be relied on as accurately representing the current state of our affairs.
We have proprietary rights to trademarks used
in this prospectus, including Kiora®. Solely for our convenience, trademarks and trade names referred to in this prospectus may appear
without the “®” or “™” symbols, but such references are not intended to indicate, in any way, that we
will not assert, to the fullest extent possible under applicable law, our rights or the rights to these trademarks and trade names. We
do not intend our use or display of other companies’ trade names, trademarks or service marks to imply a relationship with, or endorsement
or sponsorship of us by, any other companies. Each trademark, trade name, or service mark of any other company appearing in this prospectus
is the property of its respective holder.
PROSPECTUS SUMMARY
The following summary highlights information
contained elsewhere in this prospectus. It may not contain all of the information that is important to you. You should read the entire
prospectus carefully, especially the discussion regarding the risks of investing in our securities under the heading “Risk Factors”
and our financial statements and the related notes in our Amended Annual Report on Form 10-K/A for the fiscal year ended December 31,
2021 filed with the SEC on July 7, 2022 and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2022
filed with the SEC on November 9, 2022, before investing in our securities. All references to “Company” “we,”
“our” or “us” refer solely to Kiora Pharmaceuticals, Inc. and its subsidiaries and not to the persons who
manage us or sit on our Board of Directors.
Overview
We are a clinical-stage specialty pharmaceutical
company developing therapies for the treatment of ophthalmic diseases. We were formed as a Delaware corporation on December 26, 2004
under the name of EyeGate Pharmaceuticals, Inc., and changed our name to Kiora Pharmaceuticals, Inc. effective November 8,
2021. We were originally incorporated in 1998 under the name of Optis France S.A. in Paris, France.
Our lead product is KIO-301 with an initial focus
on patients with mid to later stages of disease progression due to Retinitis Pigmentosa (any and all sub-forms). KIO-301 is a potential
vision-restoring small molecule that acts as a “photoswitch” specifically designed to restore vision in patients with inherited
and age-related degenerative retinal diseases. The molecule is specifically designed to restore the eyes’ ability to perceive and
interpret light in visually impaired patients. It selectively enters viable downstream retinal ganglion cells (no longer receiving electrical
input due to degenerated rods and cones) and is intended to turn them into light sensing cells, capable of signaling the brain as to the
presence or absence of light. We initiated a Phase 1b clinical trial in the third quarter of 2022 and enrolled the first patient
in the fourth quarter of 2022. KIO-301 (formerly known as B-203) was acquired through the Bayon Therapeutics, Inc. (“Bayon”)
transaction which closed October 21, 2021.
KIO-101 is a product that focuses on patients
with Ocular Presentation of Rheumatoid Arthritis and other autoimmune diseases (“OPRA+”). KIO-101 is a next-generation,
non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (“DHODH”) with what we believe
to be best-in-class picomolar potency and a validated immune modulating mechanism designed to overcome the off-target side effects and
safety issues associated with commercially available DHODH inhibitors. In a 14-Day GLP intravenous (IV) repeated dose toxicity study
in rats, no adverse or test item related effects were observed in any of the tested parameters (mortality, clinical observations, ophthalmoscopy,
body weight and food consumption, hematology and coagulation, clinical biochemistry, organ weight, pathology and histopathology) at the
highest doses tested (1.0 mg/kg). In the fourth quarter of 2021, we reported topline safety and tolerability data from a Phase 1b
proof-of-concept (“POC”) study evaluating KIO-101 in patients with ocular surface inflammation. As a further sign of safety,
there were zero clinically significant laboratory (including liver enzymes) findings observed in both healthy patients and those with
ocular surface inflammation. We initiated a Phase 2 clinical trial in the second half of 2022 and expect to enroll patients starting
in the second quarter of 2023. KIO-101 (formerly known as PP-001) was acquired through the acquisition of Panoptes Pharma Ges.m.b.H “Panoptes”
in the fourth quarter of 2020.
In addition, we are developing KIO-201, for patients
with Persistent Corneal Epithelial Defects and patients recovering from surgical wounds, such as those undergoing photorefractive keratectomy
(“PRK”) surgery. KIO-201 is a modified form of the natural polymer hyaluronic acid, designed to protect the ocular surface
to permit re-epithelialization of the cornea and improve and maintain ocular surface integrity. KIO-201 has unique properties that help
hydrate and protect the ocular surface.
Recent Developments
Public Offering
On July 22, 2022,
we entered into an Underwriting Agreement with Ladenburg Thalmann & Co. Inc., as underwriter, pursuant to which we issued and
sold, on July 26, 2022 in a firm commitment underwritten public offering (the “Public Offering”), (i) 592,392 shares
of Common Stock, (ii) 1,280 shares of Series E Convertible Preferred Stock, (iii) 30,095,697 Class A Warrants, and
(iv) 30,095,697 Class B Warrants. Upon exercise, the warrants will convert on a 40 for 1 basis into a total of 1,504,785 common
shares. The net proceeds to us, after deducting the underwriting discount and commissions and estimated offering expenses payable by us,
were approximately $5.3 million. Each of the Class A Warrants and Class B Warrants
have an exercise price of $8.00 per share of underlying common stock. The securities were offered by us pursuant to a Registration Statement
on Form S-1 (File No. 333-264641), which was initially filed with the Securities and Exchange Commission (the “Commission”)
on May 3, 2022, amended on July 13, 2022, July 19, 2022 and July 21, 2022, and declared effective by the Commission
on July 21, 2022.
Each Class A Warrant
and Class B Warrant became exercisable following approval by our stockholders of the exercise of those warrants at the stockholder
meetings held on September 15, 2022 and September 23, 2022 and the consummation of the reverse stock split as described below.
The Class A Warrants will expire on the one-year anniversary of their initial exercise date, and the Class B Warrants will expire
on the five-year anniversary of their initial exercise date.
Reverse Stock Split
On September 23,
2022, we filed with the Secretary of State of the State of Delaware a Certificate of Amendment to our Restated Certificate of Incorporation
(the “Certificate of Amendment”), which was approved by our stockholders at our 2022 Annual Meeting of Stockholders held on
September 23, 2022 and by our Board of Directors.
The Certificate of Amendment
effected a 1-for-40 reverse stock split of our Common Stock, in which each forty (40) shares of Common Stock issued and outstanding as
of 12:01 a.m. Eastern Time on September 27, 2022 (the effective time of the reverse stock split) was combined and converted
into one share of Common Stock. While the reverse stock split decreased the number of outstanding shares of Common Stock, it did not change
the total number of shares of Common Stock authorized for issuance by us, nor did it change the par value of the Common Stock. The reverse
stock split-adjusted shares of Common Stock began trading on The Nasdaq Capital Market at the open of the market on September 27,
2022 under the new CUSIP number 49721T 309. No change was made to the trading symbol for the Common Stock, “KPRX”, in connection
with the reverse stock split.
In connection with the
reverse stock split, proportional adjustments were made to (i) the number of shares of Common Stock underlying our outstanding stock
options and warrants, (ii) the exercise price or conversion price (as applicable) of our outstanding stock options and warrants,
and (iii) the number of shares reserved for issuance under our equity incentive plan. All
share and per share amounts in this prospectus have been adjusted retroactively to reflect the reverse stock split.
Warrant
Inducement Transaction
On November 17,
2022, we entered into warrant exercise inducement offer letters (“Inducement Letters”) with certain of the investors from
the Public Offering, pursuant to which such investors agreed to exercise for cash all of their Class A Warrants to purchase 654,609
shares of our Common Stock originally issued in the Public Offering in exchange for our agreement to issue new warrants (the “Inducement
Warrants”) on substantially the same terms as the Class A Warrants, except as described below, to purchase up to 654,609 shares
of Common Stock (such issuance, the “Private Placement”). Each Inducement Warrant
is exercisable at a price per share of common stock of $5.97. Each Inducement Warrant will initially be exercisable six months
following its date of issuance, and will expire on the 18 month anniversary of their initial exercise date. We received aggregate
gross proceeds of approximately $3.12 million from the exercise of the Class A Warrants by the selling stockholders and the sale
of the Inducement Warrants.
Related-Party Transactions
We incurred expenses
of approximately $0.125 million for services to a related party vendor Ora, Inc. who is providing us with clinical study services
for KIO-301. Aron Shapiro, one of our directors, is an executive at Ora, Inc. This amount was included in accounts payable at September 30,
2022 and was subsequently paid.
The Lincoln Park Transactions
The Private Placement
On February 2, 2023,
we entered into the Securities Purchase Agreement with Lincoln Park pursuant to which we issued and sold to Lincoln Park (i) 52,798
shares of Common Stock and (ii) warrants to purchase up to 105,596 shares of Common Stock at an exercise price of $3.538 per share,
which price represents the “Minimum Price” in accordance with Nasdaq Listing Rule 5635(d) (subject to pro rata adjustments
for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction), for an aggregate
gross purchase price of $200,000, in the Private Placement. The Private Placement closed on February 3, 2023. The warrants will become
exercisable upon the six-month anniversary of the closing date (i.e., August 3, 2023), or the Initial Exercise Date, and thereafter
at any time during the five-year period following the Initial Exercise Date. If a registration statement registering the resale of the
shares of Common Stock underlying the warrants is not effective under the Securities Act and available for use by the holder of the warrants
at the time of exercise on or after the Initial Exercise Date, the warrants may be exercised by means of a “cashless” exercise
formula. The warrants do not contain any “price protection” anti-dilution protection or any “price reset” provisions
pursuant to which the exercise price of the warrants is subject to adjustment or reset at a future date or upon the occurrence of specified
or contingent events directly or indirectly related to our business or the market prices for the Common Stock, or upon any future issuance
or sale by us of shares of its capital stock or securities exercisable or exchangeable for or convertible into shares of our capital stock
at exercise or conversion prices below the exercise price of the warrants, other than standard pro rata adjustments for any reorganization,
recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction that would impact our Common Stock
generally.
On
February 2, 2023 and simultaneously with the execution of the Securities Purchase Agreement, we entered into a customary registration
rights agreement with Lincoln Park, which we refer to in this prospectus as the Private Placement Registration Rights Agreement. The Private
Placement Registration Rights Agreement provides that if, at any time during the period from and after the closing date of the Private
Placement through and including the six-month anniversary of the closing date, we propose to file a registration statement with the SEC
for our own account or for the account of one or more third parties other than we or any of our subsidiaries (including any offering to
be made on a delayed or continuous basis under Rule 415 under the Securities Act), such as the registration statement that includes
this prospectus, which we filed with the SEC pursuant to our obligations under the registration rights agreement that we entered into
with Lincoln Park relating to the Committed Equity Facility (described below) for the purpose of registering under the Securities Act
for resale by Lincoln Park shares of Common Stock that may be issued and sold by us to Lincoln Park in the Committed Equity Financing
pursuant to the Purchase Agreement, then Lincoln Park may elect to have the 52,798 shares of Common Stock that were issued and sold by
us to Lincoln Park in the Private Placement pursuant to the Securities Purchase Agreement on February 3, 2023 also included in such
registration statement in order to register under the Securities Act the resale by Lincoln Park of such 52,798 shares of Common Stock
that were issued and sold by us to Lincoln Park in the Private Placement. However, the Private Placement Registration Rights Agreement
does not afford any registration rights with respect to the warrants that were issued and sold by us to Lincoln Park in the Private Placement,
or with respect to the 105,596 shares of Common Stock underlying such warrants. Therefore, none of the warrants or the 105,596 shares
of Common Stock underlying such warrants that were issued and sold by us to Lincoln Park in the Private Placement on February 3,
2023 are being registered for resale in the registration statement that includes this prospectus, or any other registration statement
of ours that has been filed with the SEC as of the date of this prospectus.
The
52,798 shares of Common Stock and the warrants to purchase up to 105,596
shares of Common Stock that we issued and sold to Lincoln Park in the Private Placement pursuant to the Securities Purchase Agreement
on February 3, 2023, and the 105,596 shares of Common Stock in the
aggregate issuable upon full exercise of the warrants in accordance with the terms of the warrants, have been and will be issued and sold
by us to Lincoln Park in the Private Placement in reliance upon the exemptions from the registration requirements of the Securities Act
afforded by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder.
Lincoln Park has represented
to us that at no time prior to our execution of the Securities Purchase Agreement and the Private Placement Registration Rights Agreement
has Lincoln Park or its agents, representatives or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly,
any short sale (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of our Common Stock or any hedging transaction,
which establishes a net short position with respect to our Common Stock.
There are no restrictions
on future financings, rights of first refusal, participation rights, penalties or liquidated damages in the Securities Purchase Agreement
or the Private Placement Registration Rights Agreement, except that we (i) are prohibited (with certain specified exceptions) from,
among other things, until the earlier of (1) the first business day following the date a registration statement registering the shares
of Common Stock sold in the Private Placement for resale is declared effective and (2) the six-month anniversary of the closing of
the Private Placement, effecting or entering into an agreement to effect a “variable rate transaction” whereby we issue and
sell Common Stock or securities exercisable or convertible into Common Stock at a conversion price, exercise price, exchange rate or other
price that is based on and/or varies with the trading price of Common Stock at any time after the initial issuance of such securities,
that includes any reset to such prices after the initial date of issuance, or that includes any put, call, redemption, back-back, price
reset or other similar provision, subject to certain exceptions, and (ii) will be required to pay certain liquidated damages to Lincoln
Park if (A) for so long as Lincoln Park owns any shares of Common Stock, warrants or shares of Common Stock issued or issuable upon
exercise of the warrants acquired by Lincoln Park in the Private Placement (or until such earlier date as none of the warrants remain
outstanding), we fail for any reason to satisfy the current public information requirement under Rule 144(c) under the Securities
Act, until such time as such requirement is no longer required in order for Lincoln Park to resell such securities pursuant to Rule 144
under the Securities Act, or (B) we fail to deliver to Lincoln Park the shares of Common Stock, including shares of Common Stock
issuable upon exercise of the warrants, purchased by Lincoln Park in the Private Placement free of restrictive legends or any other restrictions
on transfer thereof within a specified period set forth in the Securities Purchase Agreement.
The Securities Purchase
Agreement and the Private Placement Registration Rights Agreement contain customary representations, warranties, conditions and indemnification
obligations of the parties. Copies of the Securities Purchase Agreement and the Private Placement
Registration Rights Agreement have been filed as exhibits to the registration statement that includes
this prospectus and are available electronically on the SEC’s website at www.sec.gov.
The Committed Equity
Financing
On February 3, 2023, we entered into the
Purchase Agreement with Lincoln Park, pursuant to which Lincoln Park has agreed to purchase from us up to an aggregate of $10.0 million
of our Common Stock (subject to certain limitations), from time to time and at our sole discretion over the term of the Purchase Agreement.
Also on February 3, 2023, we entered into a registration rights agreement with Lincoln Park, which we refer to in this prospectus
as the CEF Registration Rights Agreement, pursuant to which we filed with the SEC the registration statement that includes this prospectus
to register under the Securities Act for resale by Lincoln Park the shares of our Common Stock that we may elect to issue and sell to
Lincoln Park from time to time from and after the date of this prospectus in connection with the Committed Equity Financing under the
Purchase Agreement.
This
prospectus relates to the offer and resale by Lincoln Park of up to 1,052,798 shares of our Common Stock, consisting of: (i) 52,798
shares of Common Stock that we have issued and sold to Lincoln in the
Private Placement pursuant to the Securities Purchase Agreement on February 3, 2023, in which we issued and sold to Lincoln
Park 52,798 shares of Common Stock and warrants to purchase up to an aggregate of 105,596
shares of Common Stock, at a purchase price per unit consisting of one share of Common Stock and two warrants of $3.788, and for
a total purchase price of $200,000 (none of the warrants or the 105,596 shares
of Common Stock underlying such warrants are being registered for resale in the registration statement that includes this prospectus),
and (ii) up to 1,000,000 shares of Common Stock that we have reserved for issuance and sale to Lincoln Park in the Committed Equity
Financing under the Purchase Agreement from time to time after the date of this prospectus, if and when we determine to sell shares of
our Common Stock to Lincoln Park in the Committed Equity Financing under the Purchase Agreement.
We do not have the right to commence any sales
of our Common Stock to Lincoln Park under the Purchase Agreement until all of the conditions to Lincoln Park’s purchase obligations
under the Committed Equity Financing set forth in the Purchase Agreement have been satisfied (which we refer to in this prospectus as
the Commencement), including that the SEC declare effective the registration statement that includes this prospectus and a final prospectus
relating thereto is filed with the SEC. Under the Purchase Agreement, from and after the date on which the Commencement occurs, or the
Commencement Date, on any business day selected by us we may, by written notice delivered by us to Lincoln Park, direct Lincoln Park to
purchase up to 35,000 shares of Common Stock on such business day (which shall be the “purchase date” therefor), at a purchase
price per share that will be determined and fixed in accordance with the Purchase Agreement at the time we deliver such written notice
to Lincoln Park (each such purchase, a Regular Purchase), provided, however, that the maximum number of shares of Common Stock we may
sell to Lincoln Park in a Regular Purchase will be automatically increased to (i) 40,000 shares, if the closing sale price of our
Common Stock on the applicable purchase date for such Regular Purchase is not below $6.00 per share, (ii) 45,000 shares, if the closing
sale price of our Common Stock on the applicable purchase date for such Regular Purchase is not below $8.00 per share, and (iii) 50,000
shares, if the closing sale price of our Common Stock on the applicable purchase date for such Regular Purchase is not below $10.00 per
share (each of such stock and dollar amounts subject to adjustment for any reorganization, recapitalization, non-cash dividend, stock
split, reverse stock split or other similar transaction as provided in the Purchase Agreement). In any case, however, Lincoln Park’s
maximum purchase commitment in any single Regular Purchase may not exceed $1,000,000. The per share purchase price for the shares of Common
Stock sold in each such Regular Purchase, if any, will be based on prevailing market prices of our Common Stock immediately preceding
the time of sale as computed under the Purchase Agreement. We may direct Lincoln Park to purchase shares of our Common Stock in a Regular
Purchase on any business day we select as the purchase date for such Regular Purchase and as often as every business day, provided that
all shares of Common Stock subject to all prior Regular Purchases that we have effected under the Purchase Agreement, if any, have been
received by Lincoln Park before we deliver notice to Lincoln Park for such Regular Purchase in accordance with the Purchase Agreement.
In
addition to Regular Purchases described above, provided that (i) we have directed Lincoln Park to purchase the maximum amount
of Common Stock that we are then able to sell to Lincoln Park in a Regular Purchase on the applicable purchase date therefor and (ii) the
closing sale price of our Common Stock on such applicable purchase date for such Regular Purchase is not below $1.00 per share (subject
to adjustment for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction
as provided in the Purchase Agreement), we may, in our sole discretion, also direct Lincoln Park to purchase additional shares of Common
Stock in “accelerated purchases” and “additional accelerated purchases” as set forth in the Purchase Agreement,
provided further that all shares of Common Stock purchased by Lincoln Park pursuant to all prior Regular Purchases, accelerated purchases
and additional accelerated purchases (as applicable) that we have effected under the Purchase Agreement have been received by Lincoln
Park before we deliver notice to Lincoln Park for the applicable accelerated purchase (and with respect to an additional accelerated purchase,
before we deliver notice to Lincoln Park for such applicable additional accelerated purchase) in accordance with the Purchase Agreement.
The purchase price per share of Common Stock to be paid by Lincoln Park for shares of Common Stock that we elect to sell to Lincoln Park
in any accelerated purchase (or in any additional accelerated purchase, as applicable) will be based on prevailing market prices of our
Common Stock at the time of sale as computed under the Purchase Agreement.
Under the applicable Nasdaq rules, in no event
may we issue to Lincoln Park in connection with the Committed Equity Financing under the Purchase Agreement more than 359,114 shares of
our Common Stock, which number of shares is equal to 19.99% of the shares of Common Stock outstanding immediately prior to the execution
of the Purchase Agreement, which we refer to as the Exchange Cap, unless (i) we obtain stockholder approval to issue shares of Common
Stock in excess of the Exchange Cap in accordance with applicable Nasdaq rules, or (ii) the average price per share paid by Lincoln
Park for all of the shares of Common Stock that we direct Lincoln Park to purchase from us pursuant to the Purchase Agreement, if any,
equals or exceeds $3.538 per share (representing the lower of the official closing price of our Common Stock on Nasdaq on the trading
day immediately preceding the date of the Purchase Agreement and the average official closing price of our Common Stock on Nasdaq for
the five consecutive trading days ending on the trading day immediately preceding the date of the Purchase Agreement) so that the Exchange Cap limitation would not apply to issuances and sales of Common Stock in the Committed
Equity Financing under applicable Nasdaq rules. In any event, the Purchase Agreement specifically provides that we may not issue or sell
any shares of our Common Stock under the Purchase Agreement if such issuance or sale would breach any applicable Nasdaq rules or
regulations.
The Purchase Agreement also provides that we may
not under any circumstances issue or sell any shares of Common Stock to Lincoln Park under the Purchase Agreement which, when aggregated
with all other shares of Common Stock then beneficially owned by Lincoln Park and its affiliates (as calculated pursuant to Section 13(d) of
the Securities Exchange Act of 1934, as amended, or the Exchange Act, and Rule 13d-3 thereunder), would result in Lincoln Park beneficially
owning more than 9.99% of our outstanding Common Stock, which we refer to in this prospectus as the Beneficial Ownership Cap.
We will control the timing and amount of any sales
of our Common Stock to Lincoln Park pursuant to the Purchase Agreement. Lincoln Park has no right to require us to sell any shares of
Common Stock to them under the Purchase Agreement, however Lincoln Park is obligated to make purchases of our Common Stock as we may properly
direct Lincoln Park to purchase under the Purchase Agreement, upon the terms and subject to the satisfaction of the conditions set forth
therein. Neither we nor Lincoln Park may assign or transfer our respective rights and obligations under the Purchase Agreement, and no
provision of the Purchase Agreement or the CEF Registration Rights Agreement may be modified or waived by us or Lincoln Park.
Actual
sales of shares of Common Stock to Lincoln Park will depend on a variety of factors to be determined by us from time to time, including,
among others, market conditions, the trading price of the Common Stock and determinations by us as to the appropriate sources of funding
for our company and its operations. The net proceeds that we may realize from sales of Common Stock to Lincoln Park under the Purchase
Agreement, if any, will depend on the frequency and prices at which we may, from time to time at its discretion, sell shares of Common
Stock to Lincoln Park from and after the date of this prospectus. We expect that any net proceeds that may be received by us from such
sales of Common Stock to Lincoln Park in the Committed Equity Financing pursuant to the Purchase Agreement, together with the net proceeds
received by us from the sale of 52,798 shares of Common Stock and warrants to purchase up to 105,596
shares of Common Stock to Lincoln Park in the Private Placement on February 3, 2023, will be used for working capital and
general corporate purposes.
Lincoln Park has represented to us that at no
time prior to our execution of the Purchase Agreement and the CEF Registration Rights Agreement has Lincoln Park or its agents, representatives
or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any short sale (as such term is defined in Rule 200
of Regulation SHO of the Exchange Act) of our Common Stock or any hedging transaction, which establishes a net short position with respect
to our Common Stock.
There are no restrictions on future financings,
rights of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement or the CEF Registration Rights
Agreement, except that we are prohibited (with certain specified exceptions) from, among other things, until the earlier of (1) the
later of (A) the 36-month anniversary of the date of the Purchase Agreement and (B) the 36-month anniversary of the Commencement Date
(if the Commencement shall have occurred), and (2) the six-month anniversary of the effective date of termination of the Purchase
Agreement in accordance with its terms, effecting or entering into an agreement to effect a “variable rate transaction” whereby
we issue and sell Common Stock or securities exercisable or convertible into Common Stock at a conversion price, exercise price, exchange
rate or other price that is based on and/or varies with the trading price of Common Stock at any time after the initial issuance of such
securities, that includes any reset to such prices after the initial date of issuance, or that includes any put, call, redemption, back-back,
price reset or other similar provision, subject to certain exceptions.
We have the unconditional right, at any time,
for any reason and without any payment or liability to us, to terminate the Purchase Agreement upon one business day’s prior written
notice to Lincoln Park. In the event of bankruptcy proceedings by or against us that are not discharged within 90 days, the Purchase Agreement
will automatically terminate without action of any party. No termination of the Purchase Agreement will be effective during the pendency
of any Regular Purchase, accelerated purchase or additional accelerated purchase that has not then fully settled in accordance with the
Purchase Agreement.
The Purchase Agreement and the CEF Registration
Rights Agreement contain customary representations, warranties, conditions and indemnification obligations of the parties. Copies
of the agreements have been filed as exhibits to the registration statement that includes this prospectus and are available electronically
on the SEC’s website at www.sec.gov.
As of February 3, 2023, there were 1,849,270
shares of our Common Stock outstanding, of which 1,848,795 shares of our Common Stock were held by non-affiliates. Although the Purchase
Agreement provides that we may sell up to an aggregate of $10.0 million of our Common Stock to Lincoln Park, only 1,052,798 shares of
our Common Stock are being registered for resale under this prospectus, which represents the 52,798 shares that we issued to Lincoln
Park in the Private Placement and an additional 1,000,000 shares of our Common Stock that we may issue and sell to Lincoln Park in the
future in the Committed Equity Financing under the Purchase Agreement, if and when we sell shares of our Common Stock to Lincoln Park
under the Purchase Agreement. Depending on the market prices of our Common Stock at the time we elect to issue and sell shares of our
Common Stock to Lincoln Park in the Committed Equity Financing under the Purchase Agreement, we may need to register for resale under
the Securities Act additional shares of our Common Stock in order to receive aggregate gross proceeds equal to the $10.0 million total
commitment available to us under the Purchase Agreement. If all of the 1,000,000 shares of our Common Stock that may be sold to Lincoln
Park in the future in the Committed Equity Financing under the Purchase Agreement that are being registered for resale by Lincoln Park
hereunder were issued and outstanding as of the date of this prospectus (without taking into account the 19.99% Exchange Cap limitation
applicable to the Committed Equity Financing under the Purchase Agreement), such shares of our Common Stock, taken together with the
52,798 shares of Common Stock that we issued and sold to Lincoln Park on February 3, 2023 in the Private Placement, would represent
approximately 57% of the total number of shares of our Common Stock outstanding and approximately 57% of the total number of outstanding
shares of our Common Stock held by non-affiliates of the Company, in each case as of February 3, 2023.
If it becomes necessary for us to issue and sell
to Lincoln Park shares of Common Stock in excess of the Exchange Cap under the Purchase Agreement in order to receive aggregate gross
proceeds equal to $10,000,000 in the Committed Equity Financing under the Purchase Agreement, then for so long as the Exchange Cap continues
to apply to the Committed Equity Financing, we must first obtain stockholder approval to issue shares of Common Stock in excess of the
Exchange Cap under the Purchase Agreement in accordance with applicable Nasdaq rules. Furthermore, if we elect to issue and sell to Lincoln
Park more than the 1,000,000 shares of our Common Stock that we may elect to issue and sell to Lincoln Park in the Committed Equity Financing
under the Purchase Agreement that are being registered for resale by Lincoln Park hereunder, which we have the right, but not the obligation,
to do, we must first file with the SEC one or more additional registration statements to register under the Securities Act for resale
by Lincoln Park such additional shares of our Common Stock we wish to sell from time to time under the Purchase Agreement, which the SEC
must declare effective, in each case before we may elect to sell any additional shares of our Common Stock to Lincoln Park in the Committed
Equity Financing under the Purchase Agreement. Any issuance and sale by us under the Purchase Agreement of a substantial amount of shares
of Common Stock in addition to the 1,000,000 shares of Common Stock being registered for resale by Lincoln Park under this prospectus
could cause additional substantial dilution to our stockholders.
The number of shares of Common Stock relating
to the Committed Equity Financing ultimately resold by Lincoln Park through this prospectus is dependent upon the total number of shares
of Common Stock, if any, we elect to issue and sell to Lincoln Park in the Committed Equity Financing pursuant to the Purchase Agreement
from and after Commencement and during the term of the Purchase Agreement. The issuance by us of our Common Stock to Lincoln Park in the
Committed Equity Financing pursuant to the Purchase Agreement will not affect the rights or privileges of our existing stockholders, except
that the economic and voting interests of each of our existing stockholders will be diluted. Although the number of shares of Common Stock
that our existing stockholders own will not decrease, the shares of Common Stock owned by our existing stockholders will represent a smaller
percentage of our total outstanding Common Stock after any such issuance.
Our Corporate Information
Kiora Pharmaceuticals, Inc. was formed in
Delaware on December 26, 2004 under the name EyeGate Pharmaceuticals, Inc. On November 8, 2021, we completed a merger of
our wholly owned Delaware subsidiary, Kiora Pharmaceuticals, Inc. (incorporated in October 2021) into EyeGate Pharmaceuticals, Inc.,
which merger resulted in the amendment of our restated certificate of incorporation to change our name to “Kiora Pharmaceuticals, Inc.”
effective November 8, 2021 (the “Name Change”). In connection with the name change, we changed our symbol on the Nasdaq
Capital Market to “KPRX” and began using a new CUSIP number effective at the market open on November 8, 2021.We were
originally incorporated in 1998 under the name of Optis France S.A. in Paris, France. We have four wholly owned subsidiaries: Jade Therapeutics, Inc.,
Kiora Pharmaceuticals, GmbH (formerly known as Panoptes Pharma Ges.m.b.H), Bayon Therapeutics, Inc., and Kiora Pharmaceuticals Pty
Ltd (formerly known as Bayon Therapeutics Pty Ltd). Our former subsidiary, EyeGate Pharma S.A.S. was dissolved effective December 31,
2020. Our principal executive offices are located at 332 Encinitas Boulevard, Suite 102, Encinitas, California 92024, and our telephone
number is (781) 788-8869. Our website address is www.kiorapharma.com. Our website and the information contained in, or accessible
through, our website will not be deemed to be incorporated by reference into this prospectus and does not constitute part of this prospectus.
You should not rely on any such information in making your decision whether to purchase our securities.
THE OFFERING
We
are registering for resale by the selling stockholder named herein an aggregate
of 1,052,798 shares of our Common Stock as described below.
| Shares of our common stock offered by the selling stockholder: |
|
Up to 1,052,798 shares of our Common
Stock consisting of:
● 52,798
shares of Common Stock issued to Lincoln Park in the Private Placement; and
● up
to 1,000,000 shares of our Common Stock that we may issue and sell to Lincoln Park from
time to time in the Committed Equity Financing under the Purchase Agreement from and after the Commencement Date. |
| |
|
| Shares of our common stock outstanding prior to this offering |
|
1,849,270 shares of our Common
Stock, which includes the 52,798 shares issued to Lincoln Park in the Private Placement.
|
|
Shares of our common stock to be outstanding after giving effect to
the issuance of the additional 1,000,000 shares of our Common Stock reserved for issuance
and sale under the Purchase Agreement
|
|
2,849,270 shares of our Common
Stock. The actual number of shares outstanding after this offering will vary depending upon the actual number of shares of Common
Stock we elect to sell to Lincoln Park in the Committed Equity Financing under the Purchase Agreement from and after the Commencement
Date.
|
| Use of proceeds |
|
We will receive no proceeds from the sale of shares of our Common Stock
by Lincoln Park in this offering. We have received $200,000 aggregate gross proceeds under the Securities Purchase Agreement from our
sale to Lincoln Park of 52,798 shares of Common Stock and warrants to purchase up to an aggregate of 105,596 shares of Common Stock on
February 3, 2023 in the Private Placement. We may also receive up to $10.0 million aggregate gross proceeds from any sales of shares
of our Common Stock we elect to make to Lincoln Park in the Committed Equity Financing pursuant to the Purchase Agreement after the Commencement
Date, assuming that we sell the full amount of our Common Stock that we have the right, but not the obligation to sell to Lincoln Park
under the Purchase Agreement. Any proceeds that we receive from sales of shares of our Common Stock to Lincoln Park in the Committed Equity
Financing, together with the proceeds we received from Lincoln Park in the Private Placement, will be used to support our operations,
including clinical trials, for working capital and for other general corporate purposes. See “Use of Proceeds.” |
| |
|
| Risk factors |
|
Investing in our securities involves a high degree
of risk. See “Risk Factors” beginning on page 11 of this prospectus, and under similar headings in the other documents
that are incorporated by reference into this prospectus, for a discussion of information that should be considered in connection with
an investment in our securities.
|
| Nasdaq Capital Market symbol |
|
Our Common Stock is listed on The Nasdaq Capital
Market under the symbol “KPRX.” On February 2, 2023, the last reported sale price of our Common Stock on The Nasdaq Capital
Market was $3.56.
|
The number of shares of our Common
Stock to be outstanding after giving effect to the issuance of the additional 1,000,000 shares of our Common
Stock reserved for issuance and sale under the Purchase Agreement is based on 1,849,270 shares of our Common
Stock outstanding as of February 3, 2023, but does not include, as of such date:
| |
● |
334 shares of Common Stock exercised under our 2005 and 2014 Equity Incentive Plans, at a weighted-average exercise price of approximately $1,063.07 per share; |
| ● | 84,751 shares of Common Stock issuable upon exercise of options outstanding under our
2005 Equity Incentive Plan and 2014 Equity Incentive Plan, at a weighted-average exercise price of approximately $36.92 per share; |
| |
● |
4,241 shares of our Common Stock granted through a restricted stock award and released under our 2005 and 2014 Equity Incentive Plans, at a weighted-average exercise price of approximately $0 per share; |
| |
● |
30,000 shares of our Common Stock granted through a restricted stock award subject to release under our 2005 and 2014 Equity Incentive Plans, at a weighted-average exercise price of approximately $0 per share; |
| ● | 1,597,606 shares of our Common Stock issuable upon the exercise of outstanding warrants
to purchase shares of our Common Stock with a weighted-average exercise price of $21.22 per
share, other than the warrants issued to Lincoln Park in the Private Placement as noted below; |
| ● | the 105,596 warrants issued to Lincoln Park in the Private Placement, with an exercise price of $3.538 per share; |
| ● | 100,824 shares of Common Stock reserved for future issuance under our 2014 Equity Incentive
Plan; |
| ● | 191 shares of Common Stock reserved for future issuance under our 2014 Employee Stock
Purchase Plan; and |
| ● | 52 shares of Common Stock issuable upon the conversion of outstanding shares of Series D
Convertible Preferred Stock. |
RISK FACTORS
Investing in our securities involves a high
degree of risk. Before making an investment decision with respect to our securities, we urge you to carefully consider the risks described
in the “Risk Factors” sections of our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q,
as well as our Current Reports on Form 8-K, filed with the SEC and incorporated by reference into this prospectus. In addition, the
following risk factors present material risks and uncertainties associated with this offering. The risks and uncertainties incorporated
by reference into this prospectus or described below are not the only ones we face. Additional risks and uncertainties not presently known
or which we consider immaterial as of the date hereof may also have an adverse effect on our business. If any of the matters discussed
in the following risk factors were to occur, our business, financial condition, results of operations, cash flows or prospects could be
materially and adversely affected, the market price of our common stock could decline and you could lose all or part of your investment
in our securities.
Risks Related to the Offering
It is not possible to predict the actual
number of shares we may sell to Lincoln Park in the Committed Equity Financing under the Purchase Agreement, or the actual gross proceeds
resulting from those sales.
On February 3, 2023, we entered into the
Purchase Agreement with Lincoln Park, pursuant to which Lincoln Park has committed to purchase up to $10.0 million of our Common Stock
in the Committed Equity Financing, subject to certain limitations and conditions set forth in the Purchase Agreement. The shares of our
Common Stock that may be issued under the Purchase Agreement may be sold by us to Lincoln Park at our discretion from time to time over
an approximately 36-month period commencing on the Commencement Date.
We generally have the right to control the timing
and amount of any sales of our shares of Common Stock to Lincoln Park under the Purchase Agreement. Sales of our Common Stock, if any,
to Lincoln Park under the Purchase Agreement will depend upon market conditions and other factors to be determined by us. We may ultimately
decide to sell to Lincoln Park all, some or none of the shares of our Common Stock that may be available for us to sell to Lincoln Park
pursuant to the Purchase Agreement.
Because the purchase price per share to be paid
by Lincoln Park for the shares of Common Stock that we may elect to sell to Lincoln Park under the Purchase Agreement, if any, will fluctuate
based on the market prices of our Common Stock at the time we elect to sell shares to Lincoln Park pursuant to the Purchase Agreement,
if any, it is not possible for us to predict, as of the date of this prospectus and prior to any such sales, the number of shares of Common
Stock that we will sell to Lincoln Park under the Purchase Agreement, the purchase price per share that Lincoln Park will pay for shares
purchased from us under the Purchase Agreement, or the aggregate gross proceeds that we will receive from those purchases by Lincoln Park
under the Purchase Agreement.
Moreover,
although the Purchase Agreement provides that we may sell up to an aggregate of $10.0 million of our Common Stock to Lincoln Park in the
Committed Equity Financing, only 1,052,798 shares of Common Stock are being registered for
resale under the registration statement that includes this prospectus, consisting of (i) the 52,798 shares of Common Stock that we
previously issued to Lincoln Park in the Private Placement and (ii) up to 1,000,000 shares of our Common Stock that we may elect
to sell to Lincoln Park, in our sole discretion, from time to time from and after the Commencement Date in the Committed Equity Financing
under the Purchase Agreement.
If after the Commencement Date we elect to sell
to the selling stockholder all of the 1,000,000 shares of Common Stock being registered for resale under this prospectus that are available
for sale by us to the selling stockholder in purchases in the Committed Equity Financing under the Purchase Agreement, depending on the
market prices of our Common Stock at the time of such sales, the actual gross proceeds from the sale of all such shares in the Committed
Equity Financing may be substantially less than the $10.0 million total purchase commitment available to us under the Purchase Agreement,
which could materially adversely affect our liquidity.
If it becomes necessary for us to issue and sell to Lincoln Park shares
of Common Stock in excess of the Exchange Cap under the Purchase Agreement in order to receive aggregate gross proceeds equal to $10,000,000
in the Committed Equity Financing under the Purchase Agreement, then for so long as the Exchange Cap continues to apply to the Committed
Equity Financing, we must first obtain stockholder approval to issue shares of Common Stock in excess of the Exchange Cap under the Purchase
Agreement in accordance with applicable Nasdaq rules. Furthermore, if we elect to issue and sell to Lincoln Park more than the 1,000,000
shares of our Common Stock that we may elect to issue and sell to Lincoln Park in the Committed Equity Financing under the Purchase Agreement
that are being registered for resale by Lincoln Park hereunder, which we have the right, but not the obligation, to do, we must first
file with the SEC one or more additional registration statements to register under the Securities Act for resale by Lincoln Park such
additional shares of our Common Stock we wish to sell from time to time under the Purchase Agreement, which the SEC must declare effective,
in each case before we may elect to sell any additional shares of our Common Stock to Lincoln Park in the Committed Equity Financing under
the Purchase Agreement. Any issuance and sale by us under the Purchase Agreement of a substantial amount of shares of Common Stock in
addition to the 1,000,000 shares of Common Stock being registered for resale by Lincoln Park under this prospectus could cause additional
substantial dilution to our stockholders.The number of shares of our Common
Stock ultimately offered for sale by Lincoln Park is dependent upon the number of shares of Common Stock we ultimately sell to Lincoln
Park in the Committed Equity Financing under the Purchase Agreement.
Investors who buy shares at different times
will likely pay different prices.
Pursuant to the Purchase Agreement, we will have
discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold to Lincoln Park in the Committed Equity Financing.
If and when we do elect to sell shares of our Common Stock to Lincoln Park in the Committed Equity Financing pursuant to the Purchase
Agreement, after Lincoln Park has acquired such shares, Lincoln Park may resell all, some or none of such shares at any time or from time
to time in its discretion and at different prices. As a result, investors who purchase shares from Lincoln Park in this offering at different
times will likely pay different prices for those shares, and so may experience different levels of dilution and in some cases substantial
dilution and different outcomes in their investment results. Investors may experience a decline in the value of the shares they purchase
from Lincoln Park in this offering as a result of future sales made by us to Lincoln Park at prices lower than the prices such investors
paid for their shares in this offering.
We may not have access to the full amount
available in the Committed Equity Financing under the Purchase Agreement with Lincoln Park. We may require additional financing to sustain
our operations, without which we may not be able to continue operations, and the terms of subsequent financings may adversely impact our
stockholders.
We may direct Lincoln Park to purchase up to $10.0
million worth of shares of our Common Stock from time to time in the Committed Equity Financing under the Purchase Agreement over a 36-month
period generally in amounts up to 35,000 shares of our Common Stock, which may be increased to up to 50,000 shares of our Common Stock
depending on the market price of our Common Stock at the time of sale, provided that Lincoln Park’s committed obligation under such
single Regular Purchase shall not exceed $1,000,000.
Depending on the prevailing market price of our
Common Stock, we may not be able to sell shares to Lincoln Park for the maximum $10.0 million over the term of the Purchase Agreement.
We will need to seek stockholder approval before issuing more than 359,114 shares in the Committed Equity Financing under the Purchase
Agreement, unless the average price of all applicable sales of our Common Stock to Lincoln Park under the Purchase Agreement equals or
exceeds $3.538 per share (which represents the lower of (A) the official closing price of our Common Stock on Nasdaq on the trading
day immediately preceding the date of the Purchase Agreement and (B) the average official closing price of our Common Stock on Nasdaq
for the five consecutive trading days ending on the trading day immediately preceding the date of the Purchase Agreement), so that the
Exchange Cap limitation will not apply to issuances and sales of Common Stock in the Committed Equity Financing under applicable Nasdaq
rules. We are not required or permitted to issue any shares of Common Stock in the Committed Equity Financing under the Purchase Agreement
if such issuance would breach our obligations under the rules or regulations of The Nasdaq Stock Market. In addition, Lincoln Park
will not be required to purchase any shares of our Common Stock if such sale would result in Lincoln Park’s beneficial ownership
of our Common Stock exceeding 9.99% of the outstanding shares of our Common Stock. Our inability to access a portion or the full amount
available under the Purchase Agreement, in the absence of any other financing sources, could have a material adverse effect on our business.
The extent we rely on Lincoln Park as a source
of funding will depend on a number of factors including the prevailing market price of our Common Stock and the extent to which we are
able to secure working capital from other sources. If obtaining sufficient funding from Lincoln Park were to prove unavailable or prohibitively
dilutive, we will need to secure another source of funding in order to satisfy our working capital needs. Even if we sell all $10.0 million
of shares of our Common Stock in the Committed Equity Financing under the Purchase Agreement to Lincoln Park, we may still need additional
capital to finance our future production plans and working capital needs, and we may have to raise funds through the issuance of equity
or debt securities. Assuming a purchase price of $3.56 (which represents the closing price of our Common Stock on February 2, 2023),
the purchase by Lincoln Park of the 52,798 shares issued in the Private Placement and the entire 1,000,000 additional shares issuable
under the Purchase Agreement being registered hereunder would result in gross proceeds to us of only $3,747,961.
Depending on the type and the terms of any financing
we pursue, stockholders’ rights and the value of their investment in our Common Stock could be reduced. A financing could involve
one or more types of securities including Common Stock, convertible debt or warrants to acquire Common Stock. These securities could be
issued at or below the then prevailing market price for our Common Stock. In addition, if we issue secured debt securities, the holders
of the debt would have a claim to our assets that would be prior to the rights of stockholders until the debt is paid. Interest on these
debt securities would increase costs and negatively impact operating results. If the issuance of new securities results in diminished
rights to holders of our Common Stock, the market price of our Common Stock could be negatively impacted.
Should the financing we require to sustain our
working capital needs be unavailable or prohibitively expensive when we require it, the consequences could be a material adverse effect
on our business, operating results, financial condition and prospects.
Our management will have broad discretion
over the use of the net proceeds from our sale of shares of Common Stock to Lincoln Park in the Private Placement and in the Committed
Equity Financing, you may not agree with how we use the proceeds and the proceeds may not be invested successfully.
Our management will have broad discretion as to
the use of the net proceeds from our sale of shares of Common Stock to Lincoln Park in the Private Placement and in the Committed Equity
Financing, and we could use them for purposes other than those contemplated at the time of commencement of this offering. Accordingly,
you will be relying on the judgment of our management with regard to the use of those net proceeds, and you will not have the opportunity,
as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that, pending their use,
we may invest those net proceeds in a way that does not yield a favorable, or any, return for us. The failure of our management to use
such funds effectively could have a material adverse effect on our business, financial condition, operating results and cash flows.
SPECIAL NOTE REGARDING
FORWARD-LOOKING STATEMENTS
This prospectus contains, and the documents incorporated
herein by reference contain, forward-looking statements that involve risks and uncertainties. The forward-looking statements are contained
principally in the sections of this prospectus and the documents incorporated herein by reference under the captions “Prospectus
Summary,” “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations”
and “Business.” In some cases, you can identify forward-looking statements by terms such as “may,” “might,”
“will,” “objective,” “intend,” “should,” “seek,” “aim,” “think,”
“optimistic,” “strategy,” “goals,” “sees,” “new,” “guidance,”
“future,” “continue,” “drive,” “growth,” “long-term,” “develop,”
“possible,” “emerging,” “opportunity,” “pursue,” “could,” “can,”
“would,” “expect,” “believe,” “anticipate,” “project,” “target,”
“design,” “estimate,” “predict,” “potential,” “plan” or the negative of these
terms, and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect
to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place
undue reliance on these forward-looking statements. Forward-looking statements include, but are not limited to, statements about:
| |
● |
the timing and success of preclinical studies and clinical trials conducted by us and our development partners; |
| |
● |
the ability to obtain and maintain regulatory approval of our product candidates, and the labeling for any approved products; |
| |
● |
the scope, progress, expansion, and costs of developing and commercializing our product candidates; |
| |
● |
the size and growth of the potential markets for our product candidates and the ability to serve those markets; |
| |
● |
our expectations regarding our expenses and revenue, the sufficiency of our cash resources and needs for additional financing; |
| |
● |
the rate and degree of market acceptance of any of our product candidates; |
| |
● |
our expectations regarding competition; |
| |
● |
our anticipated growth strategies; |
| |
● |
our ability to attract or retain key personnel; |
| |
● |
our ability to establish and maintain development partnerships; |
| |
● |
our expectations regarding federal, state and foreign regulatory requirements; |
| |
● |
regulatory developments in the U.S. and foreign countries; |
| |
● |
our ability to obtain and maintain intellectual property protection for our product candidates; |
| |
● |
the anticipated trends and challenges in our business and the market in which we operate; |
| |
● |
the impact of the evolving COVID-19 pandemic and the global response thereto; and |
| |
● |
our use of proceeds from this offering. |
| |
|
|
| |
|
|
Any forward-looking statement made by us in this
prospectus speaks only as of the date on which it is made. Because forward-looking statements are inherently subject to risks and uncertainties,
some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking
statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved
or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an
evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict
all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking
statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
You should read this prospectus and the documents
that we reference in this prospectus and have filed as exhibits to the registration statement, of which this prospectus is a part, completely
and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking
statements by these cautionary statements.
MARKET FOR COMMON STOCK
Our common stock is listed on The Nasdaq Capital
Market under the symbol “KPRX”. On February 2, 2023, the last reported sale price of our common stock as reported by
The Nasdaq Capital Market was $3.56 per share. As of such date, we had approximately 53 stockholders of record.
DIVIDEND POLICY
We have never declared or paid any cash dividends
on our capital stock. We currently intend to retain future earnings, if any, and all currently available funds for use in the operation
of our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to our dividend
policy will be made at the discretion of our Board of Directors after considering our financial condition, results of operations, capital
requirements, business prospects and other factors the Board of Directors deems relevant, and subject to the restrictions contained in
our current or future financing instruments.
USE OF PROCEEDS
This
prospectus relates to shares of our Common Stock that may be offered and sold from time to time by Lincoln Park. We will receive no proceeds
from the sale of shares of Common Stock by Lincoln Park in this offering. We have received $200,000 aggregate gross proceeds under the
Securities Purchase Agreement from our sale to Lincoln Park of 52,798 shares of Common Stock and warrants to purchase up to an aggregate
of 105,596 shares of Common Stock on February 3, 2023 in the
Private Placement, and we may receive additional aggregate gross proceeds of up to $10.0 million from sales of common stock we may elect
to make to Lincoln Park in our sole discretion from time to time from and after the Commencement Date in the Committed Equity Financing
pursuant to the Purchase Agreement. We estimate that the total aggregate net proceeds to us from the sale of our Common Stock and Warrants
to Lincoln Park in the Private Placement and from the sale of our Common Stock to Lincoln Park in the Committed Equity Facility would
be up to $10.1 million over an approximately 36-month period, assuming that we sell the full amount of our Common Stock that we have the
right, but not the obligation, to sell to Lincoln Park in the Committed Equity Financing under the Purchase Agreement, and after other
estimated fees and expenses. See “Plan of Distribution” elsewhere in this prospectus for more information.
Any proceeds from that we receive from Lincoln
Park in the Private Placement and in the Committed Equity Financing are expected to be used, together with other available funds, to support
our operations, including clinical trials, for working capital and for other general corporate purposes. We have not yet determined the
amount of net proceeds to be used specifically for any of the foregoing purposes. The amounts and timing of these expenditures will depend
on a number of factors, such as the timing and progress of our research and development efforts, regulatory matters affecting our product
candidates and our business, and the competitive environment for our product candidates. As we are unable to predict the timing or amount
of potential issuances of all of the additional shares issuable to the Purchase Agreement, we cannot specify with certainty all of the
particular uses for the net proceeds that we will have from the sale of such additional shares. Accordingly, our management will have
broad discretion in the application of the net proceeds. We may also use a portion of the net proceeds to acquire or invest in complementary
businesses, technologies, product candidates or other intellectual property, although we have no present commitments or agreements to
do so. We may use the proceeds for purposes that are not contemplated at the time of this offering. Pending use of the proceeds as described
above, we intend to invest the net proceeds of this offering in short-term, interest-bearing, investment-grade securities or certificates
of deposit.
Based upon our historical
and anticipated future growth and our financial needs, we may engage in additional financings of a character and amount that we determine
as the need arises. We may raise additional capital through additional public or private financings, the incurrence of debt and other
available sources.
THE LINCOLN PARK TRANSACTIONS
The Private Placement
On February 2, 2023,
we entered into the Securities Purchase Agreement with Lincoln Park pursuant to which we issued and sold to Lincoln Park (i) 52,798
shares of Common Stock and (ii) warrants to purchase up to 105,596 shares of Common Stock at an exercise price of $3.538 per share
(subject to pro rata adjustments for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other
similar transaction), for an aggregate gross purchase price of $200,000, in the Private Placement. The Private Placement closed on February 3,
2023. The warrants will become exercisable on the Initial Exercise Date, which is the six-month anniversary of the closing date (i.e.,
August 3, 2023), and thereafter at any time during the five-year period following the Initial Exercise Date. If a registration statement
registering the resale of the shares of Common Stock underlying the warrants is not effective under the Securities Act and available for
use by the holder of the warrants at the time of exercise on or after the Initial Exercise Date, the warrants may be exercised by means
of a “cashless” exercise formula. The warrants do not contain any “price protection” anti-dilution protection
or any “price reset” provisions pursuant to which the exercise price of the warrants is subject to adjustment or reset at
a future date or upon the occurrence of specified or contingent events directly or indirectly related to our business or the market prices
for the Common Stock, or upon any future issuance or sale by us of shares of its capital stock or securities exercisable or exchangeable
for or convertible into shares of our capital stock at exercise or conversion prices below the exercise price of the warrants, other than
standard pro rata adjustments for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar
transaction that would impact our Common Stock generally.
On
February 2, 2023 and simultaneously with the execution of the Securities Purchase Agreement, we entered into the
Private Placement Registration Rights Agreement. The Private Placement Registration Rights Agreement provides that if, at any time during
the period from and after the closing date of the Private Placement through and including the six-month anniversary of the closing date,
we propose to file a registration statement with the SEC for our own account or for the account of one or more third parties other than
us or any of our subsidiaries (including any offering to be made on a delayed or continuous basis under Rule 415 under the Securities
Act), such as the registration statement that includes this prospectus, which was filed by us with the SEC pursuant to our obligations
under the registration rights agreement that we entered into with Lincoln Park relating to the Committed Equity Facility for the purpose
of registering under the Securities Act for resale by Lincoln Park shares of Common Stock that may be issued and sold by us to Lincoln
Park in the Committed Equity Financing pursuant to the Purchase Agreement, then Lincoln Park may elect to have the 52,798 shares of Common
Stock that were issued and sold by us to Lincoln Park in the Private Placement pursuant to the Securities Purchase Agreement on February 3,
2023 also included in such registration statement in order to register under the Securities Act the resale by Lincoln Park of such 52,798
shares of Common Stock that were issued and sold by us to Lincoln Park in the Private Placement. However, the Private Placement Registration
Rights Agreement does not afford any registration rights with respect to the warrants that were issued and sold by us to Lincoln Park
in the Private Placement, or with respect to the 105,596 shares of Common Stock underlying such warrants. Therefore, none of the warrants
or the 105,596 shares of Common Stock underlying such warrants that were issued and sold by us to Lincoln Park in the Private Placement
on February 3, 2023 are being registered for resale in the registration statement that includes this prospectus, or any other registration
statement of ours that has been filed with the SEC as of the date of this prospectus.
The
52,798 shares of Common Stock and the warrants to purchase up to 105,596
shares of Common Stock that were issued and sold by us to Lincoln Park in the Private Placement pursuant to the Securities Purchase
Agreement on February 3, 2023, and the 105,596 shares of Common Stock
in the aggregate issuable upon full exercise of the warrants in accordance with the terms of the warrants, have been and will be issued
and sold by us to Lincoln Park in the Private Placement in reliance upon the exemptions from the registration requirements of the Securities
Act afforded by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder.
Lincoln Park has represented
to us that at no time prior to our execution of the Securities Purchase Agreement and the Private Placement Registration Rights Agreement
has Lincoln Park or its agents, representatives or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly,
any short sale (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of our Common Stock or any hedging transaction,
which establishes a net short position with respect to our Common Stock.
There are no restrictions
on future financings, rights of first refusal, participation rights, penalties or liquidated damages in the Securities Purchase Agreement
or the Private Placement Registration Rights Agreement, except that we (i) are prohibited (with certain specified exceptions) from,
among other things, until the earlier of (1) the first business day following the date a registration statement registering the shares
of Common Stock sold in the Private Placement for resale is declared effective and (2) the six-month anniversary of the closing of
the Private Placement, effecting or entering into an agreement to effect a “variable rate transaction” whereby we issue and
sell Common Stock or securities exercisable or convertible into Common Stock at a conversion price, exercise price, exchange rate or other
price that is based on and/or varies with the trading price of Common Stock at any time after the initial issuance of such securities,
that includes any reset to such prices after the initial date of issuance, or that includes any put, call, redemption, back-back, price
reset or other similar provision, subject to certain exceptions, and (ii) will be required to pay certain liquidated damages to Lincoln
Park if (A) for so long as Lincoln Park owns any shares of Common Stock, warrants or shares of Common Stock issued or issuable upon
exercise of the warrants acquired by Lincoln Park in the Private Placement (or until such earlier date as none of the warrants remain
outstanding), we fail for any reason to satisfy the current public information requirement under Rule 144(c) under the Securities
Act, until such time as such requirement is no longer required in order for Lincoln Park to resell such securities pursuant to Rule 144
under the Securities Act, or (B) we fail to deliver to Lincoln Park the shares of Common Stock, including shares of Common Stock
issuable upon exercise of the warrants, purchased by Lincoln Park in the Private Placement free of restrictive legends or any other restrictions
on transfer thereof within a specified period set forth in the Securities Purchase Agreement.
The Securities Purchase
Agreement and the Private Placement Registration Rights Agreement contain customary representations, warranties, conditions and indemnification
obligations of the parties. Copies of the Securities Purchase Agreement and the Private Placement
Registration Rights Agreement have been filed as exhibits to the registration statement that includes
this prospectus and are available electronically on the SEC’s website at www.sec.gov.
The Committed Equity
Financing
General
On February 3, 2023, we entered into the
Purchase Agreement with Lincoln Park, pursuant to which Lincoln Park has agreed to purchase from us up to an aggregate of $10.0 million
of our Common Stock (subject to certain limitations), from time to time and at our sole discretion over the term of the Purchase Agreement.
Also on February 3, 2023, we entered into the CEF Registration Rights Agreement, pursuant to which we filed with the SEC the registration
statement that includes this prospectus to register under the Securities Act for resale by Lincoln Park the shares of our Common Stock
that we may elect to issue and sell to Lincoln Park from time to time from and after the date of this prospectus in connection with the
Committed Equity Financing under the Purchase Agreement.
This
prospectus relates to the offer and resale by Lincoln Park of up to 1,052,798 shares of our Common Stock, consisting of: (i) 52,798
shares of Common Stock that we have issued and sold to Lincoln in the
Private Placement pursuant to the Securities Purchase Agreement on February 3, 2023, in which we issued and sold to Lincoln
Park 52,798 shares of Common Stock and warrants to purchase up to an aggregate of 105,596
shares of Common Stock, at a purchase price per unit consisting of one share of Common Stock and two warrants of $3.788, and for
a total purchase price of $200,000 (none of the warrants or the 105,596 shares
of Common Stock underlying such warrants are being registered for resale in the registration statement that includes this prospectus),
and (ii) up to 1,000,000 shares of Common Stock that we have reserved for issuance and sale to Lincoln Park in the Committed Equity
Financing under the Purchase Agreement from time to time from and after the Commencement Date, if and when we determine to sell shares
of our Common Stock to Lincoln Park in the Committed Equity Financing under the Purchase Agreement.
We do not have the right to commence any sales
of Purchase Shares to Lincoln Park under the Purchase Agreement until all of the conditions set forth in the Purchase Agreement have been
satisfied on the Commencement Date, including that the registration statement that includes this prospectus is declared effective by the
SEC and a final prospectus relating thereto is filed with the SEC. From and after the Commencement Date, on any business day selected
by us as the purchase date therefor, we may, from time to time and at our sole discretion for a period of up to 36-months after the Commencement
Date, by written notice delivered by us to Lincoln Park, direct Lincoln Park to purchase up to 35,000 shares of Common Stock (subject
to adjustment for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction
as provided in the Purchase Agreement) in a Regular Purchase, at a purchase price per share that will be determined and fixed in accordance
with the Purchase Agreement at the time we deliver such written notice to Lincoln Park on the purchase date for such Regular Purchase.
The maximum share limit for a Regular Purchase shall be increased to higher share threshold amounts in the Purchase Agreement, up to a
maximum share limit of 50,000 shares of Common Stock (subject to adjustment for any reorganization, recapitalization, non-cash dividend,
stock split, reverse stock split or other similar transaction as provided in the Purchase Agreement), with the applicable maximum share
limit determined by whether the closing price for our Common Stock on the applicable purchase date exceeds certain price thresholds set
forth in the Purchase Agreement. In any case, however, Lincoln Park’s maximum purchase commitment in any single Regular Purchase
may not exceed $1,000,000. The per share purchase price for the shares of Common Stock sold in each such Regular Purchase, if any, will
be based on prevailing market prices of our Common Stock immediately preceding the time of sale as computed under the Purchase Agreement.
We may direct Lincoln Park to purchase shares of our Common Stock in a Regular Purchase on any business day we select as the purchase
date for such Regular Purchase and as often as every business day, provided that all shares of Common Stock subject to all prior Regular
Purchases that we have effected under the Purchase Agreement, if any, have been received by Lincoln Park before we deliver notice to Lincoln
Park for such Regular Purchase in accordance with the Purchase Agreement.
In
addition to Regular Purchases described above, provided that (i) we have directed Lincoln Park to purchase the maximum amount
of Common Stock that we are then able to sell to Lincoln Park in a Regular Purchase on the applicable purchase date therefor and (ii) the
closing sale price of our Common Stock on such applicable purchase date for such Regular Purchase is not below $1.00 per share (subject
to adjustment for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction
as provided in the Purchase Agreement), we may, in our sole discretion, also direct Lincoln Park to purchase additional shares of Common
Stock in “accelerated purchases” and “additional accelerated purchases” as set forth in the Purchase Agreement,
provided further that all shares of Common Stock purchased by Lincoln Park pursuant to all prior Regular Purchases, accelerated purchases
and additional accelerated purchases (as applicable) that we have effected under the Purchase Agreement have been received by Lincoln
Park before we deliver notice to Lincoln Park for the applicable accelerated purchase (and with respect to an additional accelerated purchase,
before we deliver notice to Lincoln Park for such applicable additional accelerated purchase) in accordance with the Purchase Agreement.
The purchase price per share of Common Stock to be paid by Lincoln Park for shares of Common Stock that we elect to sell to Lincoln Park
in any accelerated purchase (or in any additional accelerated purchase, as applicable) will be based on prevailing market prices of our
Common Stock at the time of sale as computed under the Purchase Agreement.
Under the applicable Nasdaq rules, in no event
may we issue to Lincoln Park in connection with the Committed Equity Financing under the Purchase Agreement more than the Exchange Cap
of 359,114 shares of our Common Stock, which number of shares is equal to 19.99% of the shares of Common Stock outstanding immediately
prior to the execution of the Purchase Agreement, unless (i) we obtain stockholder approval to issue shares of Common Stock in excess
of the Exchange Cap in accordance with applicable Nasdaq rules, or (ii) the average price per share paid by Lincoln Park for all
of the shares of Common Stock that we direct Lincoln Park to purchase from us pursuant to the Purchase Agreement, if any, equals or exceeds
$3.538 per share (representing the lower of the official closing price of our Common Stock on Nasdaq on the trading day immediately preceding
the date of the Purchase Agreement and the average official closing price of our Common Stock on Nasdaq for the five consecutive trading
days ending on the trading day immediately preceding the date of the Purchase Agreement)
so that the Exchange Cap limitation would not apply to issuances and sales of Common Stock in the Committed Equity Financing under applicable
Nasdaq rules. In any event, the Purchase Agreement specifically provides that we may not issue or sell any shares of our Common Stock
under the Purchase Agreement if such issuance or sale would breach any applicable Nasdaq rules or regulations.
The Purchase Agreement also provides that we may
not under any circumstances issue or sell any shares of Common Stock to Lincoln Park under the Purchase Agreement which, when aggregated
with all other shares of Common Stock then beneficially owned by Lincoln Park and its affiliates (as calculated pursuant to Section 13(d) of
the Exchange Act and Rule 13d-3 thereunder), would result in Lincoln Park beneficially
owning more than the Beneficial Ownership Cap of 9.99% of our outstanding Common Stock.
We will control the timing and amount of any sales
of our Common Stock to Lincoln Park pursuant to the Purchase Agreement. Lincoln Park has no right to require us to sell any shares of
Common Stock to them under the Purchase Agreement, however Lincoln Park is obligated to make purchases of our Common Stock as we may properly
direct Lincoln Park to purchase under the Purchase Agreement, upon the terms and subject to the satisfaction of the conditions set forth
therein. Neither we nor Lincoln Park may assign or transfer our respective rights and obligations under the Purchase Agreement, and no
provision of the Purchase Agreement or the CEF Registration Rights Agreement may be modified or waived by us or Lincoln Park. Actual sales
of shares of Common Stock to Lincoln Park will depend on a variety of factors to be determined by us from time to time, including, among
others, market conditions, the trading price of the Common Stock and determinations by us as to the appropriate sources of funding for
us and our operations.
The Purchase Agreement and the CEF Registration
Rights Agreement contain customary representations, warranties, conditions and indemnification obligations of the parties. Copies
of the agreements have been filed as exhibits to the registration statement that includes this prospectus and are available electronically
on the SEC’s website at www.sec.gov.
Purchase of Shares of our Common Stock under
the Purchase Agreement
Regular Purchases
From and after the Commencement Date, on any business
day selected by us (and provided all shares of Common Stock subject to all prior Regular Purchases have been properly delivered to Lincoln
Park in accordance with the Purchase Agreement), we may, by written notice delivered by us to Lincoln Park, direct Lincoln Park to purchase
up to 35,000 shares of our Common Stock on such business day in a Regular Purchase, provided, however, that the maximum number of shares
we may sell to Lincoln Park in a Regular Purchase may be increased to up to (i) 40,000 shares of our Common Stock, provided that
the closing sale price of our Common Stock is not below $6.00 on the purchase date, (ii) 45,000 shares of our Common Stock, provided
that the closing sale price of our Common Stock is not below $8.00 on the purchase date, and (iii) 50,000 shares of our Common Stock,
provided that the closing sale price of our Common Stock is not below $10.00 on the purchase date (such share amount limitation, the “Regular
Purchase Share Limit”). In each case, Lincoln Park’s maximum commitment in any single Regular Purchase may not exceed $1,000,000.
The purchase price per share for each such Regular
Purchase will be equal to 98.5% of the lower of:
| |
● |
the lowest sale price for our Common Stock on the purchase date for such shares of our Common Stock; and |
| |
|
|
| |
● |
the average of the three lowest closing sale prices for our Common Stock during the 10 consecutive business days ending on the business day immediately preceding the purchase date of such shares of our Common Stock. |
Accelerated Purchases
In
addition to Regular Purchases described above, on any purchase date for a Regular Purchase on which we have properly submitted a Regular
Purchase notice directing Lincoln Park to purchase the maximum number of shares of our Common Stock that we are then permitted to include
in a single Regular Purchase notice, and provided that (i) the closing price of our Common Stock on such purchase date is not below
$1.00 per share (subject to adjustment for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock
split or other similar transaction as provided in the Purchase Agreement) and (ii) all shares of Common Stock subject to all prior
purchases effected prior to such purchase date have been properly delivered to Lincoln Park in accordance with the Purchase Agreement,
we may also direct Lincoln Park to purchase an additional amount of our Common Stock, which we refer to as an Accelerated Purchase, on
the next business day following such purchase date for such corresponding Regular Purchase, which we refer to as the Accelerated Purchase
Date, not to exceed the lesser of:
| |
● |
20% of the aggregate number of shares of our Common Stock traded during all or, if certain trading volume or market price thresholds specified in the Purchase Agreement are crossed on the applicable Accelerated Purchase Date, the portion of the normal trading hours on the applicable Accelerated Purchase Date prior to such time that any one of such thresholds is crossed, which period of time on the applicable Accelerated Purchase Date we refer to as the Accelerated Purchase Measurement Period; and |
| |
|
|
| |
● |
200% of the number of purchase shares purchased pursuant to the corresponding Regular Purchase. |
The purchase price per share
for the shares subject to an Accelerated Purchase will be equal to 97% of the lower of:
| |
● |
the volume weighted average price of our Common Stock during the Accelerated Purchase Measurement Period on the applicable Accelerated Purchase Date; and |
| |
|
|
| |
● |
the closing sale price of our Common Stock on the applicable Accelerated Purchase Date. |
Additional Accelerated Purchases
We may also direct Lincoln
Park, not later than 1:00 p.m., Eastern time, on the same Accelerated Purchase Date on which an Accelerated Purchase Measurement Period
for an Accelerated Purchase has ended prior to such time, and provided that (i) the closing price of our Common Stock on the business
day immediately preceding such Accelerated Purchase Date is not below $1.00 per share (subject to adjustment for any reorganization, recapitalization,
non-cash dividend, stock split, reverse stock split or other similar transaction as provided in the Purchase Agreement) and (ii) all
shares of Common Stock subject to all prior Regular Purchases, Accelerated Purchases and Additional Accelerated Purchases, including those
prior Accelerated Purchases and Additional Accelerated Purchases effected on the same Accelerated Purchase Date as the applicable Additional
Accelerated Purchase, have been properly delivered to Lincoln Park in accordance with the Purchase Agreement prior to such time), to purchase
an additional amount of our Common Stock on such same Accelerated Purchase Date, which we refer to as an Additional Accelerated Purchase,
of up to the lesser of:
| ● | 20% of the aggregate number of shares of our Common Stock traded during the portion of the normal trading
hours on the applicable Accelerated Purchase Date determined in accordance with the Purchase Agreement, which period of time on the applicable
Accelerated Purchase Date we refer to as the Additional Accelerated Purchase Measurement Period; and |
| ● | 200% of the number of purchase shares purchased pursuant to the Regular Purchase corresponding to the
Accelerated Purchase effected on such same Accelerated Purchase Date. |
The purchase price per share
for the shares subject to an Additional Accelerated Purchase will be equal to 97% of the lower of:
| ● | the volume weighted average price of our Common Stock during the applicable Additional Accelerated Purchase
Measurement Period for such Additional Accelerated Purchase; and |
| ● | the closing sale price of our Common Stock on the applicable same Accelerated Purchase Date. |
We may, in our sole discretion,
submit multiple Additional Accelerated Purchase notices to Lincoln Park prior to 1:00 p.m., Eastern time, on a single Accelerated Purchase
Date, again provided all shares of Common Stock subject to all prior Regular Purchases, Accelerated Purchases and Additional Accelerated
Purchases, including those prior Accelerated Purchases and Additional Accelerated Purchases effected on the same Accelerated Purchase
Date as the applicable Additional Accelerated Purchase, have been properly delivered to Lincoln Park in accordance with the Purchase Agreement
prior to such time.
In the case of Regular Purchases,
Accelerated Purchases and Additional Accelerated Purchases, the purchase price per share will be equitably adjusted for any reorganization,
recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction occurring during the business days
used to compute the purchase price.
Other than as described above,
there are no trading volume requirements or restrictions under the Purchase Agreement, and we will control the timing and amount of any
sales of our Common Stock to Lincoln Park.
Events of Default
Events of default under the Purchase Agreement
include the following:
| |
● |
the effectiveness of the registration statement of which this prospectus forms a part lapses for any reason (including, without limitation, the issuance of a stop order), or any required prospectus supplement and accompanying prospectus are unavailable for the resale by Lincoln Park of our Common Stock offered hereby, and such lapse or unavailability continues for a period of 10 consecutive business days or for more than an aggregate of 30 business days in any 365-day period; |
| |
|
|
| |
● |
suspension by our principal market of our Common Stock from trading for a period of one business day; |
| |
|
|
| |
● |
the de-listing of our Common Stock from the Nasdaq Capital Market, our principal market, provided our Common Stock is not immediately thereafter trading on the New York Stock Exchange, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the NYSE American, the NYSE Arca, or the OTCQX Best Market or the OTCQB Venture Market operated by OTC Markets Group Inc. (or nationally recognized successor thereto); |
| |
|
|
| |
● |
any breach of the representations or warranties or covenants contained in the Purchase Agreement or Registration Rights Agreement that has or could have a material adverse effect on us and, in the case of a breach of a covenant that is reasonably curable, that is not cured within five business days; |
| |
|
|
| |
● |
any voluntary or involuntary participation or threatened participation in insolvency or bankruptcy proceedings by or against us; |
| |
|
|
| |
● |
if at any time we are not eligible to transfer our Common Stock electronically; or |
| |
|
|
| |
● |
if at any time the Exchange Cap (to the extent applicable under the terms of the Purchase Agreement) is reached and our stockholders have not approved the issuance of Common Stock in excess of the Exchange Cap in accordance with applicable Nasdaq rules. |
Lincoln Park does not have the right to terminate
the Purchase Agreement upon any of the events of default set forth above, although the Purchase Agreement would automatically terminate
in the event of any voluntary or involuntary participation or threatened participation in insolvency or bankruptcy proceedings by or against
us that are not discharged within 90 days. During an event of default, all of which are outside of Lincoln Park’s control, we may
not direct Lincoln Park to purchase any shares of our Common Stock under the Purchase Agreement.
Our Termination Rights
We have the unconditional right, at any time,
for any reason and without any payment or liability to us, to terminate the Purchase Agreement upon one business day’s prior written
notice to Lincoln Park. In the event of bankruptcy proceedings by or against us that are not discharged within 90 days, the Purchase Agreement
will automatically terminate without action of any party. No termination of the Purchase Agreement will be effective during the pendency
of any Regular Purchase, Accelerated Purchase or Additional Accelerated Purchase that has not then fully settled in accordance with the
Purchase Agreement.
No Short-Selling or Hedging by Lincoln Park
Lincoln Park has represented to us that at no
time prior to the Purchase Agreement has Lincoln Park or its agents, representatives or affiliates engaged in or effected, in any manner
whatsoever, directly or indirectly, any short sale (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of
our Common Stock or any hedging transaction, which establishes a net short position with respect to our Common Stock. Lincoln Park agreed
that during the term of the Purchase Agreement, it, its agents, representatives or affiliates will not enter into or effect, directly
or indirectly, any of the foregoing transactions.
Prohibitions on Certain Transactions
There are no restrictions on future financings,
rights of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement or the CEF Registration Rights
Agreement, except that we are prohibited (with certain specified exceptions) from, among other things, until the earlier of (1) the
later of (A) the 36-month anniversary of the date of the Purchase Agreement and (B) the 36-month anniversary of the Commencement Date
(if the Commencement shall have occurred), and (2) the six-month anniversary of the effective date of termination of the Purchase
Agreement in accordance with its terms, effecting or entering into an agreement to effect a “variable rate transaction” whereby
we issue and sell Common Stock or securities exercisable or convertible into Common Stock at a conversion price, exercise price, exchange
rate or other price that is based on and/or varies with the trading price of Common Stock at any time after the initial issuance of such
securities, that includes any reset to such prices after the initial date of issuance, or that includes any put, call, redemption, back-back,
price reset or other similar provision, subject to certain exceptions.
Effect of Performance of the Purchase Agreement
on Our Stockholders
All 1,000,000 shares of our Common Stock being
registered for resale hereunder which have been or may be issued or sold by us to Lincoln Park under the Purchase Agreement are expected
to be freely tradable. It is anticipated that shares registered in this offering will be sold from time to time over a period of up to
36 months commencing on the date that the registration statement including this prospectus becomes effective. The sale by Lincoln Park
of a significant amount of shares of our Common Stock registered in this offering at any given time could cause the market price of our
Common Stock to decline and to be highly volatile. Sales of our Common Stock to Lincoln Park, if any, will depend upon market conditions
and other factors to be determined by us. We may ultimately decide to sell to Lincoln Park all, some or none of the additional shares
of our Common Stock that may be available for us to sell pursuant to the Purchase Agreement. If and when we do sell additional shares
of our Common Stock to Lincoln Park, after Lincoln Park has acquired the shares of our Common Stock, Lincoln Park may resell all, some
or none of those shares of our Common Stock at any time or from time to time in its discretion. Therefore, sales to Lincoln Park by us
under the Purchase Agreement may result in substantial dilution to the interests of other holders of our Common Stock. In addition, if
we sell a substantial number of shares of our Common Stock to Lincoln Park under the Purchase Agreement, or if investors expect that we
will do so, the actual sales of shares of our Common Stock or the mere existence of our arrangement with Lincoln Park may make it more
difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect
such sales. However, we have the right to control the timing and amount of any additional sales of our Common Stock to Lincoln Park and
the Purchase Agreement may be terminated by us at any time at our discretion without any cost to us.
Although the Purchase Agreement provides that
we may sell up to an aggregate of $10.0 million of our Common Stock to Lincoln Park, only 1,052,798 shares of our Common Stock are being
registered for resale under this prospectus, which represents the 52,798 shares that we issued to Lincoln Park in the Private Placement
and an additional 1,000,000 shares of our Common Stock that we may issue and sell to Lincoln Park in the future in the Committed Equity
Financing under the Purchase Agreement, if and when we sell shares of our Common Stock to Lincoln Park under the Purchase Agreement. If it becomes necessary for us to issue and sell to Lincoln Park shares
of Common Stock in excess of the Exchange Cap under the Purchase Agreement in order to receive aggregate gross proceeds equal to $10,000,000
in the Committed Equity Financing under the Purchase Agreement, then for so long as the Exchange Cap continues to apply to the Committed
Equity Financing, we must first obtain stockholder approval to issue shares of Common Stock in excess of the Exchange Cap under the Purchase
Agreement in accordance with applicable Nasdaq rules. Furthermore, if we elect to issue and sell to Lincoln Park more than the 1,000,000
shares of our Common Stock that we may elect to issue and sell to Lincoln Park in the Committed Equity Financing under the Purchase Agreement
that are being registered for resale by Lincoln Park hereunder, which we have the right, but not the obligation, to do, we must first
file with the SEC one or more additional registration statements to register under the Securities Act for resale by Lincoln Park such
additional shares of our Common Stock we wish to sell from time to time under the Purchase Agreement, which the SEC must declare effective,
in each case before we may elect to sell any additional shares of our Common Stock to Lincoln Park in the Committed Equity Financing under
the Purchase Agreement. Any issuance and sale by us under the Purchase Agreement of a substantial amount of shares of Common Stock in
addition to the 1,000,000 shares of Common Stock being registered for resale by Lincoln Park under this prospectus could cause additional
substantial dilution to our stockholders. The number of shares of our Common
Stock ultimately offered for resale by Lincoln Park is dependent upon the number of shares of our Common Stock we ultimately decide to
sell to Lincoln Park under the Purchase Agreement.
The number of shares of Common Stock relating
to the Committed Equity Financing ultimately resold by Lincoln Park through this prospectus is dependent upon the total number of shares
of Common Stock, if any, we elect to issue and sell to Lincoln Park in the Committed Equity Financing pursuant to the Purchase Agreement
from and after Commencement and during the term of the Purchase Agreement. The issuance by us of our Common Stock to Lincoln Park in the
Committed Equity Financing pursuant to the Purchase Agreement will not affect the rights or privileges of our existing stockholders, except
that the economic and voting interests of each of our existing stockholders will be diluted. Although the number of shares of Common Stock
that our existing stockholders own will not decrease, the shares of Common Stock owned by our existing stockholders will represent a smaller
percentage of our total outstanding Common Stock after any such issuance.
The following table sets forth the amount of gross
proceeds we would receive from Lincoln Park from our sale of up to 1,000,000 shares of our Common Stock that we are registering hereby
that we may issue and sell to Lincoln Park in the future under the Purchase Agreement at varying purchase prices from and after commencement:
Assumed
Average
Purchase Price
Per Share | | |
Number of Registered
Shares of our Common
Stock to be Issued if Full Purchase(1) | | |
Percentage of Outstanding Shares of our Common Stock After Giving Effect to the
Issuance to Lincoln Park(2) | | |
Gross Proceeds from the Sale
of Shares of our Common
Stock to Lincoln Park Under
the Purchase Agreement(1) | |
| $ | 2.00 | | |
| 1,000,000 | | |
| 35.1 | % | |
| 2,000,000 | |
| $ | 3.00 | | |
| 1,000,000 | | |
| 35.1 | % | |
$ | 3,000,000 | |
| $ | 3.56 | (3) | |
| 1,000,000 | | |
| 35.1 | % | |
$ | 3,560,000 | |
| $ | 4.00 | | |
| 1,000,000 | | |
| 35.1 | % | |
$ | 4,000,000 | |
| $ | 5.00 | | |
| 1,000,000 | | |
| 35.1 | % | |
$ | 5,000,000 | |
| (1) |
Although the Purchase Agreement provides that we may sell up to $10.0 million of our Common Stock to Lincoln Park, we are only registering 1,052,798 shares of our Common Stock for resale under this prospectus, including 52,798 shares issued to Lincoln Park in the Private Placement, which may or may not cover all the shares of our Common Stock we ultimately sell to Lincoln Park under the Purchase Agreement, depending on the purchase price per share. |
| (2) |
The denominator is based
on 1,849,270 shares of our Common Stock outstanding as of February 3, 2023 (including the 52,798 shares we issued to Lincoln
Park in the Private Placement), adjusted to include the number of shares of our Common Stock set forth in the adjacent column which
we would have sold to Lincoln Park in the Committed Equity Financing pursuant to the Purchase Agreement, assuming the purchase price
in the adjacent column. The numerator is based on the number of shares of our Common Stock issuable under the Purchase Agreement at
the corresponding assumed purchase price set forth in the adjacent column, without giving effect to the Exchange Cap, or the
Beneficial Ownership Cap, and excludes the shares issued to Lincoln Park in the Private Placement. |
| (3) |
The closing sale price per share of our Common Stock on February 2, 2023. |
SELLING STOCKHOLDER
This
prospectus relates to the possible resale by the selling stockholder, Lincoln Park, of up to 1,052,798 shares of our Common Stock, consisting
of: (i) 52,798 shares of Common Stock that we have issued and sold to Lincoln in
the Private Placement pursuant to the Securities Purchase Agreement on February 3, 2023, and (ii) up to 1,000,000 shares
of Common Stock that we have reserved for issuance and sale to Lincoln Park in the Committed Equity Financing under the Purchase Agreement
from time to time from and after the Commencement Date, if and when we determine to sell shares of our Common Stock to Lincoln Park in
the Committed Equity Financing under the Purchase Agreement.
We
are filing the registration statement of which this prospectus is a part pursuant to the provisions of the CEF Registration Rights Agreement,
which we entered into with Lincoln Park on February 3, 2023 concurrently with our execution of the Purchase Agreement, in which we
agreed to provide certain registration rights with respect to sales by Lincoln Park of the shares of our Common Stock that may be issued
to Lincoln Park in the Committed Equity Financing under the Purchase Agreement. Pursuant to the Private Placement Registration Rights
Agreement, we are also registering the shares of Common Stock that we have issued and sold to Lincoln in
the Private Placement pursuant to the Securities Purchase Agreement on February 3,
2023; however, the Private Placement Registration Rights Agreement does not afford any registration rights with respect to the warrants
that were issued and sold by us to Lincoln Park in the Private Placement, or with respect to the 105,596 shares of Common Stock underlying
such warrants. Therefore, none of the warrants or the 105,596 shares of Common Stock underlying such warrants that were issued and sold
by us to Lincoln Park in the Private Placement on February 3, 2023 are being registered for resale in the registration statement
that includes this prospectus, or any other registration statement of ours that has been filed with the SEC as of the date of this prospectus.
The selling stockholder may sell some, all or
none of the shares of Common Stock. We do not know how long the selling stockholder will hold the shares of our Common Stock before selling
them, and we currently have no agreements, arrangements or understandings with the selling stockholder regarding the sale of any of the
shares of Common Stock. See “Plan of Distribution.”
The table below sets forth, to our knowledge,
information concerning the beneficial ownership of shares of our Common Stock by the selling stockholder as of February 3, 2023.
The percentages of shares owned before and after the offering are based on 1,849,270 shares of Common Stock outstanding as of February 3,
2023, which includes the 52,798 shares that we issued to Lincoln Park in the Private Placement. The information in the table below with
respect to the selling stockholder has been obtained from the selling stockholder.
Beneficial ownership is determined in accordance
with the rules of the SEC and includes voting or investment power with respect to shares. Unless otherwise indicated below, to our
knowledge, all persons named in the table have sole voting and investment power with respect to their shares of Common Stock. The inclusion
of any shares in this table does not constitute an admission of beneficial ownership for the person named below.
Name of Selling
Stockholder | |
Number of Shares of
Common Stock Owned
Prior to Offering(2) | | |
Maximum Number
of Shares of
Common Stock to be
Offered Pursuant to
this Prospectus(3) | | |
Number of Shares of Common
Stock Owned After Offering | |
| | |
Number | | |
Percent | | |
| | |
Number (4) | | |
Percent | |
| Lincoln Park Capital Fund, LLC(1) | |
| 186,000 | | |
| 9.99 | % | |
| 1,052,798 | | |
| 284,642 | | |
| 9.99 | % |
| * |
Represents less than 1.0%. |
(1) Josh Scheinfeld and Jonathan Cope, the
Managing Members of Lincoln Park Capital, LLC, the manager of Lincoln Park Capital Fund, LLC, are deemed to be beneficial owners of all
of the shares of Common Stock owned directly by Lincoln Park Capital Fund, LLC. Messrs. Cope and Scheinfeld have shared voting and
investment power over the shares of Common Stock being offered under the registration statement filed with the SEC in connection with
the transactions contemplated under the Purchase Agreement and the Registration Rights Agreement. Neither Lincoln Park Capital, LLC nor
Lincoln Park Capital Fund, LLC is a licensed broker dealer or an affiliate of a licensed broker dealer.
(2) Includes (i) the 52,798 shares of
Common Stock issued to Lincoln Park in the Private Placement on February 3, 2023, (ii) 120,375 shares of Common Stock acquired by
Lincoln Park from the Company in connection with the Company’s public offering of its Common Stock, Series E Preferred Stock
and Class A and Class B warrants to purchase common stock (each of which Class A and Class B warrants contain a 9.99% beneficial
ownership limitation provision) on July 26, 2022 (the “July 2022 Public Offering”), and (iii) up to 12,827 shares of
Common Stock issuable upon exercise of currently exercisable Class A and Class B warrants to purchase Common Stock acquired by
Lincoln Park in the July 2022 Public Offering, subject to a 9.99% beneficial ownership limitation provision contained in each of
such warrants. Excludes (i) up to 230,923 shares of Common Stock underlying Class A and Class B warrants to purchase Common Stock
acquired by Lincoln Park in the July 2022 Public Offering pursuant to a 9.99% beneficial ownership limitation provision contained in
each of such warrants, and (ii) up to 105,596 shares of Common Stock underlying the warrants purchased by Lincoln Park in the
Private Placement on February 3, 2023, which warrants and 105,596 shares of Common Stock issuable upon exercise thereof are not
being registered in the registration statement that includes this prospectus, because such warrants are not exercisable until August
3, 2023 and therefore, are not deemed to be “beneficially owned” by Lincoln Park as of the date of this prospectus under
Rule 13d-3 of the Exchange Act. Furthermore, in accordance with Rule 13d-3(d) under the Exchange Act, we have excluded
from the number of shares of our Common Stock beneficially owned prior to the offering all of the 1,000,000 shares of our Common
Stock that we may issue and sell to Lincoln Park in the Committed Equity Financing pursuant to the Purchase Agreement, from time to
time at our discretion, from and after the Commencement Date that are being registered for resale under the registration statement
that includes this prospectus, because the issuance and sale of such shares to Lincoln Park under the Purchase Agreement is solely
at our discretion and is subject to certain conditions, the satisfaction of all of which are outside of Lincoln Park’s
control, including the registration statement that includes this prospectus becoming and remaining effective under the Securities
Act. Furthermore, under the terms of the Purchase Agreement, issuances and sales of shares of our Common Stock to Lincoln Park under
the Purchase Agreement are subject to certain limitations on the amounts we may sell to Lincoln Park at any time, including the
Exchange Cap and the Beneficial Ownership Cap.
(3) Although the Purchase Agreement provides
that we may sell up to $10.0 million of our Common Stock to Lincoln Park, we are only registering 1,052,798 shares of our common stock
for resale under this prospectus, including the 52,798 shares issued to Lincoln Park in the Private Placement. Therefore, only 1,000,000
of such shares represent shares that we may issue and sell to Lincoln Park in the future in the Committed Equity Financing under the
Purchase Agreement from time to time, at our sole discretion, during the 36-month period commencing on the Commencement Date. Depending
on the price per share at which we sell our Common Stock to Lincoln Park in the Committed Equity Financing pursuant to the Purchase Agreement,
we may need to sell to Lincoln Park under the Purchase Agreement more than the 1,000,000 shares of our Common Stock relating to the Committed
Equity Financing that are being registered for resale by Lincoln Park hereunder in order to receive aggregate gross proceeds equal to
the full $10.0 million available to us under the Purchase Agreement. If we elect to issue and sell to Lincoln Park more than the 1,000,000
shares of our Common Stock relating to the Committed Equity Financing that are being registered for resale by Lincoln Park hereunder,
we must first register for resale under the Securities Act any such additional shares of our Common Stock. The number of shares relating
to the Committed Equity Financing ultimately offered for resale by Lincoln Park through this prospectus is dependent upon the number
of shares of Common Stock we sell to Lincoln Park in the Committed Equity Financing under the Purchase Agreement.
(4) Includes (i) 120,375 shares of Common Stock acquired by
Lincoln Park from the Company in connection with the July 2022 Public Offering, and (ii) up to 164,267 shares of Common Stock
issuable upon exercise of currently exercisable Class A and Class B warrants to purchase Common Stock acquired by Lincoln Park in
the July 2022 Public Offering, subject to a 9.99% beneficial ownership limitation provision contained in each of such warrants.
Excludes (i) up to 79,483 shares of Common Stock underlying Class A and Class B warrants to purchase Common Stock acquired by
Lincoln Park in the July 2022 Public Offering pursuant to a 9.99% beneficial ownership limitation provision contained in each of
such warrants, and (ii) up to 105,596 shares of Common Stock underlying the warrants purchased by Lincoln Park in the Private
Placement on February 3, 2023, which warrants and 105,596 shares of Common Stock issuable upon exercise thereof are not being
registered in the registration statement that includes this prospectus, because such warrants are not exercisable until August 3,
2023 and therefore, are not deemed to be “beneficially owned” by Lincoln Park as of the date of this prospectus under
Rule 13d-3 of the Exchange Act.
PLAN OF DISTRIBUTION
General
The shares of our Common Stock offered for resale
by this prospectus are being offered for resale by the selling stockholder, Lincoln Park Capital Fund, LLC. The shares may be sold or
distributed from time to time by the selling stockholder directly to one or more purchasers or through brokers, dealers, or underwriters
who may act solely as agents at market prices prevailing at the time of sale, at prices related to the prevailing market prices, at negotiated
prices, or at fixed prices, which may be changed. The sale of our Common Stock offered by this prospectus could be effected in one or
more of the following methods:
| |
● |
ordinary brokers’ transactions; |
| |
|
|
| |
● |
transactions involving cross or block trades; |
| |
|
|
| |
● |
through brokers, dealers, or underwriters who may act solely as agents; |
| |
|
|
| |
● |
“at the market” into an existing market for the shares of our Common Stock; |
| |
|
|
| |
● |
in other ways not involving market makers or established business markets, including direct sales to purchasers or sales effected through agents; |
| |
|
|
| |
● |
in privately negotiated transactions; or |
| |
|
|
| |
● |
any combination of the foregoing. |
In order to comply with the securities laws of
certain states, if applicable, the shares of our Common Stock offered for resale by this prospectus may be sold only through registered
or licensed brokers or dealers. In addition, in certain states, the shares of our Common Stock offered by this prospectus may not be sold
unless they have been registered or qualified for sale in the state or an exemption from the state’s registration or qualification
requirement is available and complied with.
Brokers, dealers, underwriters or agents participating
in the distribution of the shares of our Common Stock being offered for resale by Lincoln Park by this prospectus may receive compensation
in the form of commissions, discounts, or concessions from the purchasers, for whom the broker-dealers may act as agent, of shares of
our Common Stock sold by Lincoln Park through this prospectus. The compensation paid to any such particular broker-dealer by any such
purchasers of shares of our Common Stock sold by Lincoln Park may be less than or in excess of customary commissions. Neither we nor Lincoln
Park can presently estimate the amount of compensation that any agent will receive from any purchasers of shares of our common stock sold
by Lincoln Park.
We know of no existing arrangements between Lincoln
Park or any other stockholder, broker, dealer, underwriter or agent relating to the sale or distribution of the shares of our Common Stock
offered for resale by this prospectus.
We may from time to time file with the SEC one
or more supplements to this prospectus or amendments to the registration statement that includes this prospectus to amend, supplement
or update information contained in this prospectus, including, if and when required under the Securities Act, to disclose certain information
relating to a particular sale of shares of our Common Stock offered for resale by this prospectus by the selling stockholder, including
the names of any brokers, dealers, underwriters or agents participating in the distribution of such shares of our Common Stock by the
selling stockholder, any compensation paid by the selling stockholder to any such brokers, dealers, underwriters or agents, and any other
required information.
We will pay the expenses incident to the registration
under the Securities Act of the offer and resale of the shares of our Common Stock included in this prospectus by Lincoln Park. We have
agreed to indemnify Lincoln Park and certain other persons against certain liabilities in connection with the offering of shares of our
Common Stock offered for resale by this prospectus, including liabilities arising under the Securities Act or, if such indemnity is unavailable,
to contribute amounts required to be paid in respect of such liabilities. Lincoln Park has agreed to indemnify us against liabilities
under the Securities Act that may arise from certain written information furnished to us by Lincoln Park specifically for use in this
prospectus or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities.
Lincoln Park has represented to us that at no
time prior to the date of the Securities Purchase Agreement or prior to the date of the Purchase Agreement has Lincoln Park or its agents,
representatives or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any short sale (as such term is
defined in Rule 200 of Regulation SHO of the Exchange Act) of our Common Stock or any hedging transaction, which establishes a net
short position with respect to our Common Stock. Lincoln Park agreed that during the term of the Purchase Agreement, it, its agents, representatives
or affiliates will not enter into or effect, directly or indirectly, any of the foregoing transactions.
We have advised Lincoln Park that it is required
to comply with Regulation M promulgated under the Exchange Act. With certain exceptions, Regulation M precludes the selling stockholder,
any affiliated purchasers, and any broker-dealer or other person who participates in the distribution from bidding for or purchasing,
or attempting to induce any person to bid for or purchase any security which is the subject of the distribution until the entire distribution
is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of a security in connection with the
distribution of that security. All of the foregoing may affect the marketability of the securities offered by this prospectus.
This offering will terminate on the date that
all shares of our Common Stock offered for resale by this prospectus have been resold by Lincoln Park.
Our Common Stock is currently listed on The Nasdaq
Capital Market under the symbol “KPRX”.
The Private Placement
The
selling stockholder may offer and sell, from time to time, the 52,798 shares of Common Stock that we have issued and sold to Lincoln in
the Private Placement pursuant to the Securities Purchase Agreement on February 3, 2023 that are covered by this prospectus (the
“Private Placement Shares”). The following disclosure relates to the offer and sale of the Private Placement Shares
by the selling stockholder.
With respect to the offer
and resale of the Private Placement Shares through this prospectus, the selling stockholder and any underwriters, dealers or agents participating
in a distribution of the Private Placement Shares may be deemed to be “underwriters” within the meaning of the Securities
Act, and any profit on the sale of the Private Placement Shares by the selling stockholder and any commissions received by broker-dealers
may be deemed to be underwriting commissions under the Securities Act.
The selling stockholder
may agree to indemnify an underwriter, broker-dealer or agent against certain liabilities related to the sale of the securities, including
liabilities under the Securities Act.
Instead of selling the
Private Placement Shares under this prospectus, the selling stockholder may sell the Private Placement Shares in compliance with the provisions
of Rule 144 under the Securities Act, if available, or pursuant to other available exemptions from the registration requirements
of the Securities Act.
The Committed Equity Financing
Lincoln Park may offer and sell up to 1,000,000
shares of Common Stock that are covered by this prospectus (the “CEF Shares”), which we have reserved for issuance and sale
to Lincoln Park in the Committed Equity Financing under the Purchase Agreement, from time to time from and after the Commencement Date,
if and when we determine to sell shares of our Common Stock to Lincoln Park in the Committed Equity Financing under the Purchase Agreement.
Lincoln Park is an “underwriter” within
the meaning of Section 2(a)(11) of the Securities Act with respect to the offer and resale
by Lincoln Park of up to 1,000,000 CEF Shares through this prospectus.
Lincoln Park has informed us that it intends to
use an unaffiliated broker-dealer to effectuate all resales, if any, of the CEF Shares that it may in the future acquire from us in the
Committed Equity Financing pursuant to the Purchase Agreement. Each such unaffiliated broker-dealer will be an underwriter within the
meaning of Section 2(a)(11) of the Securities Act with respect to the offer and resale by Lincoln
Park of up to 1,000,000 CEF Shares through this prospectus. Lincoln Park has informed
us that, with respect to the offer and resale by Lincoln Park of up to 1,000,000 CEF
Shares through this prospectus, each such broker-dealer will receive commissions from Lincoln Park that will not exceed customary
brokerage commissions.
DESCRIPTION OF OUR CAPITAL
STOCK
General
Our authorized capital stock consists of 50,000,000
shares of Common Stock, par value $0.01 per share, and 10,000,000 shares of preferred stock, par value $0.01 per share, of which 3,750
are designated as Series A Convertible Preferred Stock, 10,000 are designated as Series B Convertible Preferred Stock, 10,000
are designated as Series C Convertible Preferred Stock, 20,000 are designated as Series D Convertible Preferred Stock, and 1,280
are designated as Series E Convertible Preferred Stock. The following description summarizes some of the terms of our restated certificate
of incorporation and second amended and restated bylaws, but does not purport to be complete and is qualified in its entirety by the provisions
of our restated certificate of incorporation and second amended and restated bylaws, copies of which have been filed as exhibits to the
registration statement of which this prospectus is a part.
There were 1,849,270 shares of our common
stock, no shares of our Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series C Convertible
Preferred Stock or Series E Preferred Stock, and 7 shares of our Series D Convertible Preferred Stock (convertible into an aggregate
of 52 shares of common stock) outstanding as of February 3, 2023, assuming no exercise of outstanding options or warrants. There
were approximately 53 holders of record of our common stock as of February 3, 2023. This number does not include beneficial owners
whose shares are held in street name.
As of February 3, 2023, there were 119,326
shares of common stock subject to outstanding options and restricted stock awards and 1,703,202 shares of common stock subject to outstanding
warrants.
Common Stock
Voting
Rights. Each holder of common stock is entitled to one vote for each share of common stock held on all matters submitted
to a vote of the stockholders, including the election of directors. Except as otherwise provided by law or our restated certificate of
incorporation or bylaws, all matters other than the election of directors submitted to the stockholders at any meeting shall be decided
by the affirmative vote of a majority of the outstanding shares of common stock present in person or represented by proxy at the meeting
and entitled to vote thereon. Directors are elected by a plurality of the votes cast at the meeting. Our restated certificate of incorporation
and second amended and restated bylaws do not provide for cumulative voting rights. Because of this, the holders of a majority of the
shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should
so choose.
Dividends. Subject
to preferences that may be applicable to any then outstanding preferred stock, the holders of our outstanding shares of common stock are
entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.
At present, we have no plans to issue dividends.
Liquidation. In
the event of our liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally
available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of
any liquidation preference granted to the holders of any outstanding shares of preferred stock.
Other
Rights and Preferences. Holders of our common stock have no preemptive, conversion or subscription rights, and there
are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of
common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock
that we may designate and issue in the future.
Fully
Paid and Nonassessable. All of our outstanding shares of common stock are fully paid and nonassessable.
Forum
Selection. Our restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative
forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i) any derivative action or proceeding
brought on our behalf, (ii) any action asserting a claim for breach of a fiduciary duty owed by any of our directors, officers or
employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General
Corporation Law, our restated certificate of incorporation or our bylaws or (iv) any action asserting a claim governed by the internal
affairs doctrine. This provision would not apply to suits brought to enforce a duty or liability
created by the Exchange Act, Securities Act, or, in each case, the rules and regulations thereunder, or any other claim for which
the U.S. federal courts have exclusive jurisdiction.
Provisions in our restated certificate of incorporation
provide that our board of directors is authorized to issue preferred stock in one or more series, to establish the number of shares to
be included in each such series and to fix the designation, powers, preferences and rights of such shares and any qualifications, limitations
or restrictions thereof. The issuance of preferred stock may have the effect of delaying, deferring or preventing a change in control
of our company without further action by the stockholders and may adversely affect the voting and other rights of the holders of common
stock. The issuance of preferred stock with voting and conversion rights may adversely affect the voting power of the holders of common
stock, including the loss of voting control to others. At present, we have no plans to issue any additional preferred stock.
Anti-Takeover Effects of Delaware Law and Our
Certificate of Incorporation and Bylaws
Some provisions of Delaware law, our restated
certificate of incorporation and our amended and restated bylaws contain provisions that could make the following transactions more difficult:
an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our
incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions
that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for
payment of a premium over the market price for our shares.
These provisions, summarized below, are intended
to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking
to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our
potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages
of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.
Undesignated
Preferred Stock. The ability of our board of directors, without action by the stockholders, to issue up to 10,000,000
shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede
the success of any attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying
changes in control or management of our company.
Stockholder
Meetings. Our amended and restated bylaws provide that a special meeting of stockholders may be called only by our chairman
of the board or chief executive officer (or president, if there is no chief executive officer), or by a resolution adopted by a majority
of our board of directors.
Requirements
for Advance Notification of Stockholder Nominations and Proposals. Our amended and restated bylaws establish advance notice
procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election
as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.
Elimination
of Stockholder Action by Written Consent. Our restated certificate of incorporation and amended and restated bylaws eliminate
the right of stockholders to act by written consent without a meeting.
Staggered
Board. Our board of directors is divided into three classes. The directors in each class serve for a three-year term,
one class being elected each year by our stockholders. This system of electing and removing directors may tend to discourage a third-party
from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders
to replace a majority of the directors.
Removal
of Directors. Our restated certificate of incorporation provides that no member of our board of directors may be removed
from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than
two-thirds (2/3) of the total voting power of all of our outstanding voting stock then entitled to vote in the election of directors.
Stockholders
Not Entitled to Cumulative Voting. Our restated certificate of incorporation does not permit stockholders to cumulate
their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our common stock entitled
to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that
holders of our preferred stock may be entitled to elect.
Delaware
Anti-Takeover Statute. We are subject to Section 203 of the Delaware General Corporation Law, which prohibits persons
deemed to be “interested stockholders” from engaging in a “business combination” with a publicly held Delaware
corporation for three years following the date these persons become interested stockholders unless the business combination is, or the
transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception
applies. Generally, an “interested stockholder” is a person who, together with affiliates and associates, owns, or within
three years prior to the determination of interested stockholder status did own, 15% or more of a corporation’s voting stock. Generally,
a “business combination” includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to
the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved
in advance by the board of directors.
Amendment
of Charter Provisions. The amendment of any of the above provisions, except for the provision making it possible for our
board of directors to issue preferred stock, would require approval by holders of at least 66 2/3% of the total voting power of all
of our outstanding voting stock.
The provisions of Delaware law, our restated certificate
of incorporation and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and,
as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or
rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board and
management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise
deem to be in their best interests.
Transfer Agent and Registrar
The transfer and warrant agent and registrar for
our common stock is VStock Transfer, LLC.
Listing
Shares of our Common Stock are listed on The Nasdaq
Capital Market under the symbol “KPRX.”
LEGAL MATTERS
Certain legal matters with respect to the validity
of the securities offered by this prospectus will be passed upon for us by Burns & Levinson LLP, Boston, MA.
EXPERTS
The consolidated balance sheets of Kiora Pharmaceuticals, Inc.
as of December 31, 2021 and 2020, and the related consolidated statements of operations and comprehensive loss, stockholders’
equity, and cash flows for each of the years then ended, have been audited by EisnerAmper LLP, independent registered public accounting
firm, as stated in their report, which is incorporated herein by reference, which report includes an emphasis of matter paragraph regarding
the correction of a misstatement and an explanatory paragraph about the existence of substantial doubt concerning the Company’s
ability to continue as a going concern. Such financial statements have been incorporated herein by reference in reliance on the report
of such firm given upon their authority as experts in accounting and auditing.
WHERE YOU CAN FIND MORE INFORMATION
We have filed with the SEC a registration statement
on Form S-1 under the Securities Act with respect to the securities being offered by this prospectus. This prospectus does not contain
all of the information in the registration statement and its exhibits. For further information with respect to us and the common stock
offered by this prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to
the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the
copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all
respects by this reference.
We are subject to the information requirements
of the Exchange Act and, in accordance therewith, file annual, quarterly and special reports, proxy statements and other information with
the SEC. These documents may be accessed through the SEC’s electronic data gathering, analysis and retrieval system, or EDGAR, via
electronic means, including the SEC’s home page on the Internet (www.sec.gov).
We post on our public website (www.kiorapharma.com)
our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports
filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after we electronically
file such material with, or furnish it to, the SEC. Our website and the information contained on that site, or connected to that site,
are not incorporated into and are not a part of this prospectus.
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
The SEC allows us to incorporate by reference
the information and reports we file with it under File No. 001-36672, which means that we can disclose important information to you by
referring you to those publicly available documents. The information incorporated by reference is an important part of this prospectus,
and information that we file later with the SEC will automatically update and supersede the information already incorporated by reference.
We are incorporating by reference the documents listed below:
| ● | Our Current Reports on Form 8-K filed with the SEC on January 11,
2022, February 1,
2022, February 14,
2022, February 28,
2022, March 23, 2022, April 26,
2022, May 23, 2022, May
31, 2022, June 21, 2022,
July 26, 2022, August
4, 2022, August 25, 2022,
September 16, 2022, September
23, 2022, September 26,
2022, October 13, 2022,
November 21, 2022, January
3, 2023, and February 3, 2023 (in each case, except for information contained therein which is furnished rather than filed); |
| ● | The description of our common stock contained in our registration statement on Form 8-A12B filed with
the SEC on July 28, 2015 and
amended on July 30, 2015;
and |
| ● | All future documents filed by us with the SEC pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange
Act, including all filings made after the date of the filing of this registration statement and prior to the effectiveness of this registration
statement, prior to the termination of the offering of the underlying securities; provided, however, that we are not incorporating by
reference any additional documents or information furnished and not filed with the SEC. |
Any statement contained in a document incorporated or deemed to
be incorporated by reference in this prospectus is modified or superseded for purposes of the prospectus to the extent that a
statement contained in this prospectus or in any other subsequently filed document that also is or is deemed to be incorporated by
reference herein modifies or supersedes such statement.
Upon request, we will provide, without charge,
to each person, including any beneficial owner, to whom a copy of this prospectus is delivered a copy of the documents incorporated by
reference into this prospectus. You may request a copy of these filings, and any exhibits we have specifically incorporated by reference
as an exhibit in this prospectus, at no cost by writing or telephoning us at the following address:
Kiora Pharmaceuticals, Inc.
332 Encinitas Boulevard, Suite 102
Encinitas, California 92024
Telephone: (781) 788-8869
This prospectus is part of a registration statement
we filed with the SEC. We have incorporated exhibits into this registration statement. You should read the exhibits carefully for provisions
that may be important to you.
You should rely only on the information incorporated
by reference or provided in this prospectus or any prospectus supplement. We have not authorized anyone to provide you with different
information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that
the information in this prospectus or in the documents incorporated by reference is accurate as of any date other than the date on the
front of this prospectus or those documents.
1,052,798 Shares of Common Stock
PROSPECTUS
, 2023
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
| Item 13. |
Other Expenses of Issuance and Distribution. |
We are paying all expenses of the offering. No
portion of these expenses will be borne by the selling stockholder. The selling stockholder, however, will pay any other expenses incurred
in selling their Common Stock, including any brokerage commissions or costs of sale. Following is an itemized statement of all expenses
in connection with the issuance and distribution of the securities to be registered. All of the amounts shown are estimates, except
for the SEC Registration Fees.
| Securities and Exchange Commission registration fee | |
$ | 413 | |
| Legal Fees and Expenses | |
| 50,000 | |
| Accounting Fees and Expenses | |
| 25,000 | |
| Miscellaneous Fees and Expenses | |
| 30,000 | |
| Total | |
$ | 105,413 | |
| Item 14. |
Indemnification of Directors and Officers. |
Our amended and restated certificate of incorporation
contains provisions that eliminate, to the maximum extent permitted by the General Corporation Law of the State of Delaware, the personal
liability of our directors for monetary damages for breach of their fiduciary duties as directors. Our amended and restated bylaws provide
that we must indemnify our directors and officers and may indemnify our employees and other agents to the fullest extent permitted by
the General Corporation Law of the State of Delaware.
Sections 145 and 102(b)(7) of the General
Corporation Law of the State of Delaware provide that a corporation may indemnify any person made a party to an action by reason of the
fact that he or she was a director, officer, employee or agent of the corporation or is or was serving at the request of a corporation
against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by
him or her in connection with such action if he or she acted in good faith and in a manner he or she reasonably believed to be in, or
not opposed to, the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause
to believe his or her conduct was unlawful, except that, in the case of an action by or in right of the corporation, no indemnification
may generally be made in respect of any claim as to which such person is adjudged to be liable to the corporation.
We have entered into indemnification agreements
with our directors and executive officers, in addition to the indemnification provided for in our amended and restated bylaws, and intend
to enter into indemnification agreements with any new directors and executive officers in the future. We have purchased and intend to
maintain insurance on behalf of any person who is or was a director or officer of us against any loss arising from any claim asserted
against him or her and incurred by him or her in any such capacity, subject to certain exclusions. See also “Undertakings”
set out in response to Item 17 herein.
| Item 15. |
Recent Sales of Unregistered Securities. |
Set forth below is information regarding the shares
of common stock and preferred stock and the warrants issued, and options granted, by us in the three years preceding the filing of this
registration statement that were not registered under the Securities Act.
| |
(1) |
On September 29, 2019, we entered into a Securities Purchase Agreement with Armistice Capital Master Fund, Ltd. (the “Investor”), pursuant to which we issued to the Investor in a private placement 15,000 shares of common stock and warrants to purchase 15,000 shares of common stock for an aggregate purchase price of $1.875 million. The private placement closed on October 2, 2019. The warrants have an exercise price of $125 per share, subject to adjustments as provided under the terms of the warrants, and became exercisable on the six month anniversary of their issuance date. The warrants are exercisable for five years from the issuance date. |
| |
|
|
| |
(2) |
On December 31, 2019, we entered into a Securities Purchase Agreement with certain institutional investors providing for the issuance of 12,500 shares of common stock with total gross proceeds of $5.0 million. The closing of the offering occurred on January 3, 2020. H.C. Wainwright & Co., LLC acted as the placement agent in connection with the offering. We agreed to pay the placement agent an aggregate fee equal to 7% of the aggregate gross proceeds received by from the sale of the securities in the transaction plus a management fee equal to 1% of the aggregate gross proceeds received from the sale of the securities in the transaction. In addition, we also agreed to issue to the placement agent or its designees warrants to purchase up to 625 shares of common stock. The warrants have an exercise price of $500 per share of common stock, and will be exercisable for five years from the effective date of the offering. |
| |
|
|
| |
(3) |
On December 18, 2020, we entered into a Share Purchase Agreement with the shareholders of Panoptes Pharma Ges.m.b.H (“Panoptes”). Pursuant to the agreement, we acquired all of the outstanding equity interests of Panoptes, and Panoptes became a wholly-owned subsidiary of the Company. The consideration paid by us to the former shareholders of Panoptes at closing in connection with the acquisition, after adjustment as provided in the Share Purchase Agreement and including consideration paid to the sellers’ financial advisor, was comprised of (i) 22,106 shares of the common stock, (ii) 45.8923 shares of Series D Convertible Preferred convertible into an aggregate of 325 shares of common stock, and (iii) cash payments in an aggregate amount of approximately $220,577. Additionally, 1,500 shares of Series D Preferred Stock convertible into an aggregate of approximately 10,617 shares of common stock may be issued after a period of 18 months subject to adjustments for potential post-closing working capital and/or indemnification claims relating to breaches of representations, warranties and covenants contained in the Share Purchase Agreement. The Series D Convertible Preferred Stock has a stated value of $1,000 per share and a conversion price of $141.284 per share. The Series D Convertible Preferred Stock is only entitled to dividends in the event dividends are paid on shares of common stock and will not have any preferences over shares of common stock or any voting rights, except in limited circumstances. |
| |
|
|
| |
(4) |
On January 5, 2021, we entered into a Securities Purchase Agreement with the Investor, pursuant to which we agreed to issue to the Investor in a private placement 1,531,101 shares of its common stock and warrants to purchase 38,278 shares of common stock for an aggregate purchase price of approximately $8.0 million. The private placement closed on January 6, 2021. The warrants have an exercise price of $209 per share and became exercisable on the six month anniversary of their issuance date. The warrants are exercisable for five years from the issuance date. |
| |
|
|
| |
(5) |
On
August 9, 2021, we entered into a Securities Purchase Agreement with several institutional and accredited investors for
the sale of 116,721 shares common stock in a registered direct offering. Concurrently with the sale of the shares, we also sold to the
investors unregistered warrants to purchase up to an aggregate of 58,361 shares of common stock. The gross proceeds to us from the offerings
were approximately $10.75 million, before deducting the placement agent’s fees and other offering expenses, and excluding the proceeds,
if any, from the exercise of the warrants. Subject to certain ownership limitations, the warrants were immediately exercisable
upon issuance at an exercise price equal to $89.60 per share of common stock, subject to adjustments as provided under the terms of the
warrants. The warrants are exercisable for five and one-half years from the initial exercise date. The closing occurred on August 11,
2021. We agreed to pay H.C. Wainwright & Co., LLC, the placement agent for the offerings, an aggregate cash fee equal
to 7% of the aggregate gross proceeds received from the offerings plus a management fee equal to 1% of the aggregate gross proceeds received
from the sale of the securities in the offerings. In addition, we also agreed to issue to the placement agent or its designees warrants
to purchase up to 5,836 shares of common stock. The warrants have an exercise price of $115.124 per share of common stock, and will be
exercisable for five years from the commencement of the sales pursuant to the offering.
|
| |
(6) |
On October 21, 2021, we entered into a Stock
Purchase Agreement with the former stockholders of Bayon Therapeutics, Inc. (“Bayon”). Pursuant to the agreement, we
acquired all of the outstanding equity interests of Bayon, and Bayon became our wholly-owned subsidiary of the Company. The consideration
paid by us to the former Bayon stockholders at closing in connection with the acquisition, after adjustment as provided in the agreement,
was comprised of 845 shares of common stock. In addition to the consideration set forth above, the former Bayon stockholders are eligible
to receive up to $7.1 million in additional payments based on clinical trial and FDA approval milestones for Bayon’s product candidates,
as set forth in the agreement. In each case, we may elect to pay the applicable milestone payment either (i) in cash, or (ii) by
issuing shares of common stock, provided that we may not issue shares of common stock under the agreement that, in the aggregate, exceed
5% of the number of shares of common stock outstanding immediately prior to the consummation of the acquisition unless approval of the
Company’s stockholders is obtained.
|
| |
|
|
| (7) |
|
On November 17,
2022, we entered into Inducement Letters with certain investors from our August 2022 public offering pursuant to which such investors
agreed to exercise for cash all of their Class A Warrants to purchase 654,609 shares of our Common Stock originally issued in the
Public Offering in exchange for our agreement to issue new Inducement Warrants on substantially the same terms as the Class A Warrants,
except as described below, to purchase up to 654,609 shares of Common Stock, in the Private Placement. Each
Inducement Warrant is exercisable at a price per share of common stock of $5.97. Each Inducement Warrant will initially be
exercisable six months following its date of issuance, and will expire on the 18 month anniversary of their initial exercise date.
|
| |
|
|
| (8) |
|
On February 2, 2023, we entered into a securities purchase agreement with Lincoln Park whereby we issued 52,798 shares of Common Stock and warrants to purchase 105,596 shares of Common Stock to Lincoln Park in the Private Placement. The combined purchase price in the Private Placement was $3.788 per share and two warrants. Each warrant is exercisable at a price per share of common stock of $3.538, will initially be exercisable six months following its date of issuance, and will expire on the five year anniversary of its initial exercise date. |
| |
|
|
| (9) |
|
On February 3, 2023, we entered into the Purchase Agreement with Lincoln Park, pursuant to which we have the right to sell to Lincoln Park up to $10.0 million in shares of Common Stock, subject to certain limitations, from time to time over the 36 month period commencing on the date that a registration statement covering the resale of the shares is declared effective by the SEC. |
The offers, sales and issuances of the securities
described in this Item 15 were deemed to be exempt from registration under the Securities Act in reliance on Section 4(a)(2) of
the Securities Act and Rule 506 promulgated under Regulation D promulgated thereunder as transactions by an issuer not involving
a public offering. The recipients of securities in each of these transactions acquired the securities for investment only and not with
a view to or for sale in connection with any distribution thereof, and appropriate legends were affixed to the securities issued in these
transactions.
| Item 16. |
Exhibits and Financial Statement Schedules. |
(a) Exhibits.
See the Exhibit Index immediately before the Signature Pages.
(b) Financial Statement Schedules.
All schedules have been omitted because they are
either inapplicable or the required information has been given in the financial statements or notes thereto.
The undersigned registrant hereby undertakes:
| (1) |
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: |
| |
(a) |
To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, |
| |
(b) |
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement, |
| |
(c) |
To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement. |
Provided, however,
that paragraphs (1)(a), (1)(b) and (1)(c) above do not apply if the information required to be included in a post-effective
amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to
Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration
statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.
| (2) |
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
| (3) |
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. |
| (4) |
That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser: |
| |
(a) |
If the registrant is relying on Rule 430B: |
| |
(i) |
Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and |
| |
(ii) |
Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. |
| |
(b) |
If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be a part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. |
| (5) |
That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the registrant undertakes that in a primary offering of securities of the registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: |
| |
(a) |
Any preliminary prospectus or prospectus of the registrant relating to the offering required to be filed pursuant to Rule 424; |
| |
(b) |
Any free writing prospectus relating to the offering prepared by or on behalf of the registrant or used or referred to by the registrant; |
| |
(c) |
The portion of any other free writing prospectus relating to the offering containing material information about registrant or its securities provided by or on behalf of the registrant; and |
| |
(d) |
Any other communication that is an offer in the offering made by an registrant to the purchaser. |
| (6) |
That, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
| (7) |
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the forgoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. |
EXHIBIT INDEX
Exhibit
Number |
|
|
Description of Exhibit |
| 2.1** |
|
|
Stock Purchase Agreement, dated as of March 7, 2016, by and among the Registrant and the Sellers named therein (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on March 7, 2016 and incorporated by reference thereto). |
| 2.2** |
|
|
Share Purchase Agreement, dated as of December 18, 2020, by and among the Registrant and the Sellers named therein (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on December 21, 2020 and incorporated by reference thereto). |
| 2.3** |
|
|
Stock Purchase Agreement, dated as of October 21, 2021, by and among the Registrant and the Sellers named therein (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on October 26, 2021 and incorporated by reference thereto). |
| 3.1 |
|
|
Restated Certificate of Incorporation of the Registrant (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on February 20, 2015 and incorporated by reference thereto). |
| 3.2 |
|
|
Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant, filed July 10, 2018 (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on July 11, 2018 and incorporated by reference thereto). |
| 3.3 |
|
|
Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant, filed August 28, 2019 (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on August 29, 2019 and incorporated by reference thereto). |
| 3.4 |
|
|
Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant, filed June 25, 2020 (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on November 8, 2021 and incorporated by reference thereto). |
| 3.5 |
|
|
Certificate of Ownership and Merger of the Registrant, filed November 5, 2021 (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on June 26, 2020 and incorporated by reference thereto). |
| 3.6 |
|
|
Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant, filed September 26, 2022 (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on September 26, 2022 and incorporated by reference thereto). |
| 3.7 |
|
|
Third Amended and Restated By-laws of the Registrant (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on August 4, 2022 and incorporated by reference thereto). |
| 3.8 |
|
|
Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on June 27, 2016 and incorporated by reference thereto). |
| 3.9 |
|
|
Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on June 14, 2017 and incorporated by reference thereto). |
| 3.10 |
|
|
Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on April 17, 2018 and incorporated by reference thereto). |
| 3.11 |
|
|
Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on December 21, 2020 and incorporated by reference thereto). |
| 3.12 |
|
|
Form of Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on July 26, 2022 and incorporated by reference thereto). |
| 4.1 |
|
|
Specimen Stock Certificate evidencing the shares of common stock (previously filed as an exhibit to the Registrant’s Registration Statement on Form S-1 filed on July 30, 2014 and incorporated by reference thereto). |
| 4.2 |
|
|
Form of Common Stock Purchase Warrant, dated June 14, 2017 (previously filed as an exhibit to the Registrant’s Registration Statement on Form S-1 filed on June 5, 2017 and incorporated by reference thereto). |
| 4.3 |
|
|
Form of Common Stock Purchase Warrant, dated April 17, 2018 (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on April 13, 2018 and incorporated by reference thereto). |
| 4.4 |
|
|
Form of Common Stock Purchase Warrant, dated October 2, 2019 (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on September 30, 2019 and incorporated by reference thereto). |
| 4.5 |
|
|
Form of Common Stock Purchase Warrant, dated January 3, 2020 (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on December 31, 2019 and incorporated by reference thereto). |
| 4.6 |
|
|
Form of Common Stock Purchase Warrant, dated January 6, 2021 (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on January 6, 2021 and incorporated by reference thereto). |
| 4.7 |
|
|
Form of Common Stock Purchase Warrant, dated August 11, 2021 (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on August 10, 2021 and incorporated by reference thereto). |
| 4.8 |
|
|
Form of Placement Agent Warrant, dated August 11, 2021 (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on August 10, 2021 and incorporated by reference thereto). |
| 4.9 |
|
|
Form of Class A Warrant (previously filed as an exhibit to Amendment No.3 to the Registrant’s Registration Statement on Form S-1/A filed on July 21, 2022 and incorporated by reference thereto). |
| 4.10 |
|
|
Form of Class B Warrant (previously filed as an exhibit to Amendment No. 3 to the Registrant’s Registration Statement on Form S-1/A filed on July 21, 2022 and incorporated by reference thereto). |
| 4.11 |
|
|
Form of Warrant Agency Agreement by and between the Registrant and VStock Transfer, LLC (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on July 26, 2022 and incorporated by reference thereto). |
| 4.12 |
|
|
Form of Common Stock Purchase Warrant, dated November 22, 2022 (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on November 21, 2022 and incorporated by reference thereto). |
| 4.13 |
|
|
Form of Common Stock Purchase Warrant, dated February 3, 2023 (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on February 3, 2023 and incorporated by reference thereto). |
| 5.1* |
|
|
Opinion of Burns & Levinson LLP. |
| 10.1# |
|
|
2005 Equity Incentive Plan, as amended (previously filed as an exhibit to the Registrant’s Registration Statement on Form S-1 filed on July 30, 2014 and incorporated by reference thereto). |
| 10.2# |
|
|
2014 Equity Incentive Plan, as amended (previously filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q filed on August 12, 2021 and incorporated by reference thereto). |
| 10.3# |
|
|
Employee Stock Purchase Plan (previously filed as an exhibit to Amendment No. 3 to the Registrant’s Registration Statement on Form S-1 filed on September 12, 2014 and incorporated by reference thereto). |
| 10.4 |
|
|
Form of Indemnification Agreement (previously filed as an exhibit to the Registrant’s Registration Statement on Form S-1 filed on July 30, 2014 and incorporated by reference thereto). |
| 10.5# |
|
|
Form of Notice of Stock Option Grant pertaining to the 2014 Equity Incentive Plan (previously filed as an exhibit to the Registrant’s Registration Statement on Form S-1 filed on July 30, 2014 and incorporated by reference thereto). |
| 10.6# |
|
|
Form of Notice of Stock Unit Award pertaining to the 2014 Equity Incentive Plan (previously filed as an exhibit to the Registrant’s Registration Statement on Form S-1 filed on July 30, 2014 and incorporated by reference thereto). |
| 10.7† |
|
|
Intellectual Property License Agreement, dated as of September 26, 2018, by and between the Registrant and SentrX Animal Care, Inc. (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on October 2, 2018 and incorporated by reference thereto). |
| 10.8 |
|
|
Kiora Pharmaceuticals, Inc. Amended and Restated Change in Control Severance Plan (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on December 3, 2019 and incorporated by reference thereto). |
| 10.9†† |
|
|
Exclusive Sub-License Agreement, dated as of September 12, 2013, by and between Jade Therapeutics, Inc. and Biotime, Inc. (previously filed as an exhibit to the Registrant’s Annual Report on Form 10-K filed on March 4, 2020 and incorporated by reference thereto). |
| 10.10†† |
|
|
Amendment No. 1 to Sub-License Agreement, dated as of September 18, 2015, by and between Jade Therapeutics, Inc. and Biotime, Inc. (previously filed as an exhibit to the Registrant’s Annual Report on Form 10-K filed on March 4, 2020 and incorporated by reference thereto). |
| 10.11†† |
|
|
Amendment No. 2 to Sub-License Agreement, dated as of February 17, 2016, by and between Jade Therapeutics, Inc. and Biotime, Inc. (previously filed as an exhibit to the Registrant’s Annual Report on Form 10-K filed on March 4, 2020 and incorporated by reference thereto). |
| 10.12 |
|
|
Registration Rights Agreement, dated as of December 18, 2020, by and among the Registrant and the Sellers listed therein (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on December 21, 2020 and incorporated by reference thereto). |
| 10.13 |
|
|
Registration Rights Agreement, dated as of January 5, 2021, by and among the Registrant and the Purchasers listed therein (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on January 6, 2021 and incorporated by reference herein). |
| 10.14# |
|
|
Separation Agreement, dated as of January 31, 2022, by and between the Registrant and Stephen From. (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on February 1, 2022 and incorporated by reference thereto) |
| 10.15†† |
|
|
Patent and Know How Assignment Agreement, dated as of July 2, 2013, by and between Panoptes Pharma Ges.m.b.H and 4SC Discovery GmbH (previously filed as an exhibit to the Registrant’s Annual Report on Form 10-K filed on March 25, 2021 and incorporated by reference thereto). |
| 10.16†† |
|
|
Patent License Agreement, dated as of July 2, 2013, by and between Panoptes Pharma Ges.m.b.H. and 4SC Discovery GmbH (previously filed as an exhibit to the Registrant’s Annual Report on Form 10-K filed on March 25, 2021 and incorporated by reference thereto). |
| 10.17# |
|
|
Employment Agreement, dated as of July 22, 2021, by and between the Registrant and Brian M. Strem (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on July 26, 2021 and incorporated by reference thereto). |
| 10.18# |
|
|
Employment Agreement, dated as of October 21, 2021, by and between the Registrant and Eric J. Daniels (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on October 26, 2021 and incorporated by reference thereto). |
| 10.19# |
|
|
Consulting Agreement, dated as of March 9, 2022, by and between the Registrant and Danforth Consulting, LLC (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on April 26, 2022 and incorporated by reference thereto). |
| 10.20# |
|
|
Offer Letter, dated as of August 17, 2022, by and between the Registrant and Melissa Tosca (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on September 16, 2022 and incorporated by reference thereto). |
| 10.21 |
|
|
Form of Inducement Letter, dated as of November 22, 2022 (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on November 21, 2022 and incorporated by reference thereto). |
| 10.22** |
|
|
Purchase Agreement dated February 3, 2023 by and between the Registrant and Lincoln Park Capital, LLC (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on February 3, 2023 and incorporated herein by reference thereto). |
| 10.23 |
|
|
Securities Purchase Agreement dated February 2, 2023 by and between the Registrant and Lincoln Park Capital, LLC (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on February 3, 2023 and incorporated herein by reference thereto). |
| 10.24 |
|
|
Registration Rights Agreement dated February 2, 2023 by and between the Registrant and Lincoln Park Capital, LLC (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on February 2, 2023 and incorporated herein by reference thereto). |
| 10.25** |
|
|
Registration Rights Agreement dated February 3, 2023 by and between the Registrant and Lincoln Park Capital, LLC (previously filed as an exhibit to the Registrant’s Current Report on Form 8-K filed on February 3, 2023 and incorporated herein by reference thereto). |
| 21.1 |
|
|
Subsidiaries of the Registrant (previously filed as an exhibit to the Registrant’s Annual Report on Form 10-K filed on April 15, 2022 and incorporated by reference thereto). |
| 23.1* |
|
|
Consent of EisnerAmper LLP. |
| 23.2* |
|
|
Consent of Burns & Levinson LLP (included in Exhibit 5.1). |
| 24.1* |
|
|
Power of Attorney (see signature page hereto). |
| 107* |
|
|
Calculation of Registration Fee |
| | * | Filed
herewith. |
| | | |
| ** | Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K.
The registrant hereby undertakes to furnish copies of any of the omitted schedules and exhibits upon request by the U.S. Securities and
Exchange Commission. |
| † | Confidential treatment requested as to portions of the exhibit. Confidential materials omitted and filed separately with the Securities
and Exchange Commission. |
| †† | Certain confidential portions of this exhibit were omitted because the identified confidential portions (i) are not material
and (ii) would be competitively harmful if publicly disclosed. |
| | | |
| | # | Management
contract or compensatory plan or arrangement. |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant
has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of
Encinitas, State of California, on this 3rd day of February, 2023.
| KIORA PHARMACEUTICALS, INC. |
| | |
|
| By: |
/s/ Brian M. Strem, Ph.D. |
| | |
Brian M. Strem, Ph.D. |
| | |
President and Chief Executive Officer |
KNOW ALL BY THESE PRESENTS, that each person whose
signature appears below hereby constitutes and appoints Brian M. Strem, Ph.D. and Melissa Tosca, and each of them singly (with full power
to each of them to act alone), as such person’s true and lawful attorney-in-fact and agent, with full power of substitution and
resubstitution, for such person and in such person’s name, place and stead, in any and all capacities, to sign any or all amendments
(including, without limitation, post-effective amendments) to this registration statement (or any registration statement for the same
offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933), and to file the same,
with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said
attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done
in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming
all that said attorney-in-fact and agent, or any substitute or substitutes of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities
Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
| Signature |
|
Title |
|
Date |
| /s/ Brian M. Strem, Ph.D. |
|
President, Chief Executive Officer and Director |
|
February 3, 2023 |
| Brian M. Strem, Ph.D. |
|
(principal executive officer) |
|
|
| |
|
|
|
|
| /s/ Melissa Tosca |
|
Executive Vice President of Finance |
|
February 3, 2023 |
| Melissa Tosca |
|
(principal financial and accounting officer) |
|
|
| |
|
|
|
|
| /s/ Paul Chaney |
|
Chairman |
|
February 3, 2023 |
| Paul Chaney |
|
|
|
|
| |
|
|
|
|
| /s/ Kenneth Gayron |
|
Director |
|
February 3, 2023 |
| Kenneth Gayron |
|
|
|
|
| |
|
|
|
|
| /s/ Praveen Tyle |
|
Director |
|
February 3, 2023 |
| Praveen Tyle |
|
|
|
|
| |
|
|
|
|
| /s/ David Hollander |
|
Director |
|
February 3, 2023 |
| David Hollander |
|
|
|
|
| |
|
|
|
|
| /s/ Aron Shapiro |
|
Director |
|
February 3, 2023 |
| Aron Shapiro |
|
|
|
|
| |
|
|
|
|
| /s/ Erin Parsons |
|
Director |
|
February 3, 2023 |
| Erin Parsons |
|
|
|
|
Kiora Pharmaceuticals (NASDAQ:KPRX)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 12월(12) 2024
Kiora Pharmaceuticals (NASDAQ:KPRX)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
